Delaware
|
|
83-0480694
|
(State or other jurisdiction of incorporation or organization)
|
|
(I.R.S. Employer Identification Number)
|
Title of Each Class
|
|
Name of Exchange on Which Registered
|
Common Stock, $0.00001 par value per share
|
|
NASDAQ Stock Market LLC
|
Large accelerated filer
|
o
|
|
Accelerated filer
|
x
|
|
Non-accelerated filer
|
o
|
(Do not check if smaller reporting company)
|
Smaller reporting company
|
o
|
|
|
|
Page
|
|
|
|
Item 1.
|
||
Item 1A.
|
||
Item 1B.
|
||
Item 2.
|
||
Item 3.
|
||
Item 4.
|
||
|
|
|
|
|
|
Item 5.
|
||
Item 6.
|
||
Item 7.
|
||
Item 7A.
|
||
Item 8.
|
||
Item 9.
|
||
Item 9A.
|
||
Item 9B.
|
||
|
|
|
|
|
|
Item 10.
|
||
Item 11.
|
||
Item 12.
|
||
Item 13.
|
||
Item 14.
|
||
|
|
|
|
|
|
Item 15.
|
||
|
||
|
||
|
•
|
Superior Value Proposition.
Our vertically integrated infrastructure eliminates significant frictional costs that constrain most of our competitors, which allows us to provide superior value to our members.
|
•
|
Proprietary Database and Technology Platform.
Our custom-built technology platform and proprietary database contain 17 years of pet health records and give us unique insights into how to both manage our business and accurately price our medical plan subscriptions.
|
•
|
Strong Relationship with Veterinary Community.
We have invested significant time and energy communicating our value proposition to thousands of veterinarians. We partner with a nationwide sales force to communicate the benefits of our medical plan to veterinarians through in-person visits; we refer to these partners and their associates, collectively, as our Territory Partners.
|
•
|
Trupanion Express
TM
.
Our software solution Trupanion Express
TM
enables us to pay veterinarian invoices directly, often in less than five minutes, without any paperwork. Trupanion Express
TM
integrates with veterinarians’ practice management software, giving us access to more data, reducing our claims handling expense and giving us the ability to deliver a significantly better experience to our members compared to the traditional reimbursement model.
|
•
|
Referrals from third-parties.
We actively promote the value of our medical plan with veterinarians, veterinary affiliates (including purchasing groups and other veterinary membership organizations), corporate employee benefit providers, and shelters and breeders to introduce our medical plan to their clients.
|
•
|
Referrals from existing members.
For the year ended
December 31, 2016
,
24%
of our new pet enrollments were generated from existing members adding a pet or referring their friends and family.
|
•
|
Online.
We believe most of our members spend some time researching pet medical coverage online as part of their decision-making process. A significant portion of the members we acquire from online leads come through our paid search marketing, email marketing, social media marketing and search engine optimization initiatives.
|
•
|
licensing of APIC to transact its line of business and approval and issuance of its certificate of authority;
|
•
|
establishing minimum levels of capital and reserves required by APIC to operate as an ongoing insurance company;
|
•
|
assessing the officers and directors of APIC to ensure a minimum level of competency and trustworthiness;
|
•
|
licensing of individual producers and agents and business entities marketing and selling insurance products and of claims adjusters settling claims;
|
•
|
admittance of assets to statutory surplus and regulating the type of investments in which APIC can invest;
|
•
|
regulating premium rate levels for the insurance products APIC offers;
|
•
|
approving policy forms APIC issues;
|
•
|
regulating unfair trade and claims practices; and
|
•
|
establishing reserve requirements and solvency standards.
|
•
|
We must file periodic information reports with the NY DFS, including information concerning our capital structure, ownership, financial condition and general business operations.
|
•
|
New York regulates certain transactions between APIC and our other affiliated entities, including the fee levels payable by APIC to affiliates that provide services to APIC.
|
•
|
New York law restricts the ability of any one person to acquire certain levels of our voting securities without prior regulatory approval. State insurance holding company regulations generally provide that no person, corporation or other entity may acquire control of an insurance company, or a controlling interest in any parent company of an insurance company, without the prior approval of such insurance company’s domiciliary state insurance regulator. Any person acquiring, directly or indirectly, 10% or more of the voting securities of an insurance company is presumed to have acquired “control” of the company. To obtain approval of any change in control, the proposed acquirer must file with the applicable insurance regulator an application disclosing, among other information, its background, financial condition, the financial condition of its affiliates, the source and amount of funds by which it will effect the acquisition, the criteria used in determining the nature and amount of consideration to be paid for the acquisition, proposed changes in the management and operations of the insurance company and other related matters. In considering an application to acquire control of an insurer, the insurance commissioner generally will consider such factors as the experience, competence and financial strength of the applicant, the integrity of the applicant’s board of directors and executive officers, the acquirer’s plans for the management and operation of the insurer and any anti-competitive results that may arise from the acquisition.
|
•
|
New York law restricts the ability of APIC to pay dividends to its holding company parent. These restrictions are based in part on the prior year’s statutory income and surplus. In general, dividends up to specified levels are considered ordinary and may be paid without prior approval, and dividends in larger amounts, or extraordinary dividends, are subject to approval by the NY DFS. An extraordinary dividend or distribution is defined as a dividend or distribution that, in the aggregate in any 12-month period, exceeds the lesser of (i) 10% of surplus as of the preceding December 31 or (ii) the insurer’s adjusted net investment income for such 12-month period, not including realized capital gains.
|
•
|
the continued positive market presence, reputation and growth of our company and of the referral sources;
|
•
|
the effectiveness of referral sources;
|
•
|
the decision of any such referral source to support one or more of our competitors;
|
•
|
the interest of the referral sources’ customers or clients in the medical plan we offer;
|
•
|
the relationship and level of trust between Territory Partners and veterinarians, and between us and the referral source;
|
•
|
the percentage of the referral sources’ customers or clients that submit applications or use trial certificates to enroll in a medical plan through our website or contact center;
|
•
|
our ability to implement or maintain any marketing programs, including trial certificates, in any jurisdiction; and
|
•
|
our ability to work with the referral source to implement any changes in our marketing initiatives, including website changes, infrastructure and technology and other programs and initiatives necessary to generate positive consumer experiences.
|
•
|
improve our market penetration through efficient and effective sales and marketing programs to attract new members;
|
•
|
maintain high retention rates;
|
•
|
increase the lifetime value per pet to, in turn, enable us to spend more on sales and marketing programs;
|
•
|
maintain positive relationships with veterinarians and other referral sources, and convince them to recommend our medical plan;
|
•
|
maintain positive relationships with and increase the number and efficiency of Territory Partners;
|
•
|
continue to offer a superior value medical plan with competitive features and rates;
|
•
|
accurately price our medical plan subscriptions in relation to actual membership claims costs and operating expenses and achieve required regulatory approval for pricing changes;
|
•
|
provide our members with superior member service, including a timely and efficient claims experience and by recruiting, integrating and retaining skilled and experienced claims personnel who can appropriately and efficiently adjudicate member claims;
|
•
|
generate new and maintain existing relationships and programs in our other business segment;
|
•
|
recruit, integrate and retain skilled, qualified and experienced sales department professionals who can demonstrate our value proposition to new and existing members;
|
•
|
react to changes in technology and challenges in the industry, including from existing and new competitors;
|
•
|
increase awareness of and positive associations with our brand; and
|
•
|
successfully respond to any regulatory matters and defend any litigation.
|
•
|
the competitiveness of the medical plan we offer, including its perceived value, coverage, simplicity and fairness;
|
•
|
changes in consumer shopping behaviors due to circumstances outside of our control, such as economic conditions and consumers’ ability or willingness to pay for a pet medical plan;
|
•
|
the quality of and changes to the consumer experience, including on our website or with our contact center or claims department;
|
•
|
regulatory requirements, including those that make the experience on our website cumbersome or difficult to navigate or that hinder our call center or claims department’s ability to speak with potential members quickly and in a way that is conducive to converting leads, enrolling new pets, and/or resolving member concerns;
|
•
|
system failures or interruptions in the operation of our abilities to write policies or operate our website or contact center; and
|
•
|
changes in the mix of consumers who are referred to us through various member acquisition channels, such as veterinary referrals, existing members adding a pet and referring their friends and family members and other third-party referrals and online member acquisition channels.
|
•
|
the efficacy and viability of our sales and marketing programs;
|
•
|
the perceived value of our medical plan;
|
•
|
quality of service provided by our contact center and claims professionals, including the fairness, ease and timeliness of our claims administration process;
|
•
|
actions of our competitors, Territory Partners, veterinarians and other referral sources;
|
•
|
positive or negative publicity, including regulatory pronouncements and material on the Internet or social media;
|
•
|
regulatory and other government-related developments; and
|
•
|
litigation-related developments.
|
•
|
our ability to retain our current members and grow our member base;
|
•
|
the level of operating expense we elect to incur related to sales and marketing and technology and development initiatives that are discretionary in nature;
|
•
|
the effectiveness of our sales and marketing programs;
|
•
|
our ability to improve veterinarians’ and other third-parties’ willingness to recommend our medical plan;
|
•
|
the timing, volume and severity of our claims and the adequacy of our claims reserve;
|
•
|
our ability to accurately price our medical plans and achieve required regulatory pricing approvals;
|
•
|
regulatory limitations or other constraints on our ability or our willingness to implement pricing changes;
|
•
|
the level of demand for and the cost of our medical plan subscriptions or those of our competitors;
|
•
|
fluctuations in applicable foreign currency exchange rates;
|
•
|
the perceived value of our medical plan to veterinarians and pet owners;
|
•
|
spending decisions by our members and prospective members;
|
•
|
our costs and expenses, including pet acquisition costs and claims expenses;
|
•
|
our ability to expand the scope and efficiency of our Territory Partner network;
|
•
|
our ability to effectively manage our growth;
|
•
|
the effects of increased competition in our business;
|
•
|
our ability to keep pace with changes in technology and our competitors;
|
•
|
the impact of any security incidents or service interruptions;
|
•
|
costs associated with defending any regulatory action or litigation or with enforcing our intellectual property, contractual or other rights;
|
•
|
the impact of economic conditions on our revenue and expenses; and
|
•
|
changes in government regulation affecting our business.
|
•
|
we may be unable to maintain or secure favorable relationships with strategic partners;
|
•
|
our strategic partners may not be successful in creating leads;
|
•
|
our strategic partners could terminate their relationships with us;
|
•
|
we may not experience a consistent correlation between revenues and expenditures related to the partnership, and
|
•
|
bad publicity and other issues faced by our strategic partners could negatively impact us.
|
•
|
reducing the availability of our cash flow for our operations, capital expenditures, future business opportunities and other purposes;
|
•
|
limiting our flexibility in planning for, or reacting to, changes in our business and the industries in which we operate, which could place us at a competitive disadvantage compared to our competitors that may have less debt;
|
•
|
limiting our ability to borrow additional funds; and
|
•
|
increasing our vulnerability to general adverse economic and industry conditions.
|
•
|
regulatory rules and practices, foreign exchange controls, tariffs, tax laws and treaties that are different than those we operate under in the United States, Canada and Puerto Rico and that carry a greater risk of unexpected changes;
|
•
|
the costs and resources required to modify our technology and sell our medical plan in non-English speaking countries;
|
•
|
the costs and resources required to modify our medical plan appropriately to suit the needs and expectations of residents and veterinarians in such foreign countries;
|
•
|
our data analytics platform may have limited applicability in foreign countries, which may impact our ability to develop adequate underwriting criteria and accurately price subscriptions to our medical plan in such countries;
|
•
|
increased expenses incurred in establishing and maintaining office space and equipment for our international operations;
|
•
|
technological incompatibility;
|
•
|
fluctuations in exchange rates between the U.S. dollar and foreign currencies in markets where we do business;
|
•
|
difficulties in attracting and retaining personnel with experience in international operations;
|
•
|
difficulties in modifying our business model in a manner suitable for any particular foreign country, including any modifications to our Territory Partner model to the extent we determine that our existing model is not suitable for use in foreign countries;
|
•
|
our lack of experience in marketing to consumers and veterinarians, and encouraging online marketing, in foreign countries;
|
•
|
our relative lack of industry connections in many foreign countries;
|
•
|
difficulties in managing operations due to language barriers, distance and time zone differences, staffing, cultural differences and business infrastructure constraints, including difficulty in obtaining foreign and domestic visas;
|
•
|
application of foreign laws and regulations to us, including more stringent or materially different insurance, employment, consumer and data protection laws;
|
•
|
the uncertainty of protection for intellectual property rights in some countries;
|
•
|
greater risk of a failure of foreign employees to comply with applicable U.S. and foreign laws, including antitrust regulations, the U.S. Foreign Corrupt Practices Act and any trade regulations ensuring fair trade practices; and
|
•
|
general economic and political conditions in these foreign markets.
|
•
|
No Action Level
: Insurer’s total adjusted capital is equal to or greater than 200% of the Authorized Control Level.
|
•
|
Company Action Level
: Insurer’s total adjusted capital is less than 200% but greater than 150% of the Authorized Control Level. When at this level, an insurer must prepare and submit a financial plan to the NY DFS for review and approval. Generally, a risk-based capital plan would identify the conditions that contributed to the Company Action Level and include the insurer’s proposed plans for increasing its risk-based capital in order to satisfy the No Action Level. The failure to provide the NY DFS with a risk-based capital plan on a timely basis or the inability of the NY DFS and the insurer to mutually agree on an appropriate risk-based capital plan could trigger a Regulatory Action Level outcome, subject to the insurer’s right to a hearing on the issue.
|
•
|
Regulatory Action Level
: Insurer’s total adjusted capital is less than 150% but greater than 100% of the Authorized Control Level. When at this level, an insurer generally must provide a risk-based capital plan to the NY DFS and be subject to examination or analysis by the NY DFS to the extent it deems necessary, including such corrective actions as the NY DFS may require.
|
•
|
Authorized Control Level
: Insurer’s total adjusted capital is less than 100% but greater than 70% of the Authorized Control Level. At this level, the NY DFS generally could take remedial actions that it determines necessary to protect the insurer’s assets, including placing the insurer under regulatory control.
|
•
|
Mandatory Control Level
: Insurer’s total adjusted capital is less than 70% of the Authorized Control Level. At this level, the NY DFS generally is required to take steps to place the insurer under regulatory control, even if the insurer is still solvent.
|
•
|
grant and revoke licenses to transact insurance business;
|
•
|
conduct inquiries into the insurance-related activities and conduct of agents and agencies and others in the sales, marketing and promotional channels;
|
•
|
require and regulate disclosure in connection with the sale and solicitation of insurance policies;
|
•
|
authorize how, by which personnel and under what circumstances insurance premiums can be quoted and published and an insurance policy sold;
|
•
|
approve which entities can be paid commissions from carriers and the circumstances under which they may be paid;
|
•
|
regulate the content of insurance-related advertisements, including web pages, and other marketing practices;
|
•
|
approve policy forms, require specific benefits and benefit levels and regulate premium rates;
|
•
|
impose fines and other penalties; and
|
•
|
impose continuing education requirements.
|
•
|
variations in our operating results, earnings per share, cash flows from operating activities, and key financial and operational metrics, and how those results compare to analyst expectations;
|
•
|
forward-looking guidance that we provide to the public and industry and financial analysts related to future revenue and profitability, and any change in that guidance or our failure to achieve the results reflected in that guidance;
|
•
|
the net increases in the number of members, either independently or as compared with published expectations of industry, financial or other analysts that cover our company;
|
•
|
changes in the estimates of our operating results or changes in recommendations by securities analysts that elect to follow our common stock;
|
•
|
announcements of changes to our medical plan, strategic alliances or significant agreements by us or by our competitors;
|
•
|
announcements by us or by our competitors of mergers or other strategic acquisitions, or rumors of such transactions involving us or our competitors;
|
•
|
recruitment or departure of key personnel;
|
•
|
the economy as a whole and market conditions in our industry;
|
•
|
trading activity by a limited number of stockholders who together beneficially own a majority of our outstanding common stock;
|
•
|
the number of shares of our stock trading on a regular basis; and
|
•
|
any other factors discussed in these risk factors.
|
•
|
establish a classified board of directors so that not all members of our board are elected at one time;
|
•
|
permit only the board of directors to establish the number of directors and fill vacancies on the board;
|
•
|
provide that directors may only be removed “for cause” and only with the approval of two-thirds of our stockholders;
|
•
|
require super-majority voting to amend some provisions in our restated certificate of incorporation and restated bylaws;
|
•
|
authorize the issuance of “blank check” preferred stock that our board could use to implement a stockholder rights plan (also known as a “poison pill”);
|
•
|
eliminate the ability of our stockholders to call special meetings of stockholders;
|
•
|
prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders;
|
•
|
prohibit cumulative voting; and
|
•
|
establish advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings.
|
|
Fiscal Year 2016
|
|
Fiscal Year 2015
|
||||||||||||
|
High
|
|
Low
|
|
High
|
|
Low
|
||||||||
1st Quarter
|
$
|
9.85
|
|
|
$
|
7.82
|
|
|
$
|
8.47
|
|
|
$
|
6.70
|
|
2nd Quarter
|
$
|
15.92
|
|
|
$
|
9.54
|
|
|
$
|
8.50
|
|
|
$
|
7.41
|
|
3rd Quarter
|
$
|
16.93
|
|
|
$
|
13.52
|
|
|
$
|
8.63
|
|
|
$
|
6.83
|
|
4th Quarter
|
$
|
17.18
|
|
|
$
|
14.75
|
|
|
$
|
9.90
|
|
|
$
|
6.40
|
|
Company/Index
|
|
7/18/2014
|
|
9/30/2014
|
|
|
12/31/2014
|
|
|
3/31/2015
|
|
|
6/30/2015
|
|
|
9/30/2015
|
|
|
12/31/2015
|
|
|
3/31/2016
|
|
|
6/30/2016
|
|
|
9/30/2016
|
|
|
12/31/2016
|
|
||||||||||||
Trupanion Inc.
|
|
$
|
100.00
|
|
|
$
|
74.57
|
|
|
$
|
60.82
|
|
|
$
|
70.19
|
|
|
$
|
72.28
|
|
|
$
|
66.23
|
|
|
$
|
85.61
|
|
|
$
|
86.40
|
|
|
$
|
116.23
|
|
|
$
|
148.25
|
|
|
$
|
136.14
|
|
S&P Small Cap 600
|
|
100.00
|
|
|
95.62
|
|
|
104.65
|
|
|
108.46
|
|
|
108.31
|
|
|
97.91
|
|
|
101.16
|
|
|
103.45
|
|
|
106.67
|
|
|
113.98
|
|
|
126.19
|
|
|||||||||||
NASDAQ- 100 Technology Sector Index
|
|
100.00
|
|
|
101.85
|
|
|
108.79
|
|
|
108.08
|
|
|
105.62
|
|
|
98.09
|
|
|
106.25
|
|
|
107.61
|
|
|
108.77
|
|
|
127.51
|
|
|
131.81
|
|
|
|
Years Ended
December 31, |
||||||||||||||||||
|
|
2016
|
|
2015
|
|
2014
|
|
2013
|
|
2012
|
||||||||||
|
|
(in thousands, except share and per share data)
|
||||||||||||||||||
Consolidated Statements of Operations Data:
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Revenue:
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Subscription business
|
|
$
|
173,356
|
|
|
$
|
133,406
|
|
|
$
|
103,502
|
|
|
$
|
76,413
|
|
|
$
|
55,352
|
|
Other business
|
|
14,874
|
|
|
13,557
|
|
|
12,408
|
|
|
7,416
|
|
|
178
|
|
|||||
Total revenue
|
|
188,230
|
|
|
146,963
|
|
|
115,910
|
|
|
83,829
|
|
|
55,530
|
|
|||||
Cost of revenue:
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Subscription business
(1)
|
|
141,321
|
|
|
109,428
|
|
|
85,169
|
|
|
61,394
|
|
|
44,185
|
|
|||||
Other business
|
|
13,621
|
|
|
12,306
|
|
|
10,867
|
|
|
6,791
|
|
|
134
|
|
|||||
Total cost of revenue
|
|
154,942
|
|
|
121,734
|
|
|
96,036
|
|
|
68,185
|
|
|
44,319
|
|
|||||
Gross profit:
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Subscription business
|
|
32,035
|
|
|
23,978
|
|
|
18,333
|
|
|
15,019
|
|
|
11,167
|
|
|||||
Other business
|
|
1,253
|
|
|
1,251
|
|
|
1,541
|
|
|
625
|
|
|
44
|
|
|||||
Total gross profit
|
|
33,288
|
|
|
25,229
|
|
|
19,874
|
|
|
15,644
|
|
|
11,211
|
|
|||||
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Sales and marketing
(1)
|
|
15,247
|
|
|
15,231
|
|
|
11,608
|
|
|
9,091
|
|
|
7,149
|
|
|||||
Technology and development
(1)
|
|
9,534
|
|
|
11,215
|
|
|
9,899
|
|
|
4,888
|
|
|
3,406
|
|
|||||
General and administrative
(1)
|
|
15,205
|
|
|
15,558
|
|
|
14,312
|
|
|
8,652
|
|
|
6,195
|
|
|||||
Total operating expenses
|
|
39,986
|
|
|
42,004
|
|
|
35,819
|
|
|
22,631
|
|
|
16,750
|
|
|||||
Operating loss
|
|
(6,698
|
)
|
|
(16,775
|
)
|
|
(15,945
|
)
|
|
(6,987
|
)
|
|
(5,539
|
)
|
|||||
Interest expense
|
|
218
|
|
|
325
|
|
|
6,726
|
|
|
609
|
|
|
535
|
|
|||||
Other (income) expense, net
|
|
(58
|
)
|
|
(9
|
)
|
|
(1,487
|
)
|
|
671
|
|
|
252
|
|
|||||
Loss before income taxes
|
|
(6,858
|
)
|
|
(17,091
|
)
|
|
(21,184
|
)
|
|
(8,267
|
)
|
|
(6,326
|
)
|
|||||
Income tax expense (benefit)
|
|
38
|
|
|
114
|
|
|
(7
|
)
|
|
(92
|
)
|
|
84
|
|
|||||
Net loss
|
|
$
|
(6,896
|
)
|
|
$
|
(17,205
|
)
|
|
$
|
(21,177
|
)
|
|
$
|
(8,175
|
)
|
|
$
|
(6,410
|
)
|
Net loss attributable to common stockholders
|
|
$
|
(6,896
|
)
|
|
$
|
(17,205
|
)
|
|
$
|
(21,177
|
)
|
|
$
|
(8,175
|
)
|
|
$
|
(8,147
|
)
|
Net loss per share attributable to common stockholders—basic and diluted
(2)
|
|
$
|
(0.24
|
)
|
|
$
|
(0.62
|
)
|
|
$
|
(1.64
|
)
|
|
$
|
(6.23
|
)
|
|
$
|
(9.76
|
)
|
Weighted average number of shares outstanding used to compute net loss per share attributable to common stockholders—basic and diluted
(2)
|
|
28,527,602
|
|
|
27,638,443
|
|
|
12,934,477
|
|
|
1,312,019
|
|
|
834,648
|
|
|
|
Years Ended
December 31, |
||||||||||||||||||
|
|
2016
|
|
2015
|
|
2014
|
|
2013
|
|
2012
|
||||||||||
Other Financial and Operational Data
(3)
:
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Total pets enrolled
|
|
343,649
|
|
|
291,818
|
|
|
232,450
|
|
|
182,497
|
|
|
127,704
|
|
|||||
Total subscription pets enrolled
|
|
323,233
|
|
|
272,636
|
|
|
215,491
|
|
|
168,405
|
|
|
125,387
|
|
|||||
Monthly average revenue per pet
|
|
$
|
47.82
|
|
|
$
|
45.04
|
|
|
$
|
44.14
|
|
|
$
|
42.56
|
|
|
$
|
41.99
|
|
Lifetime value of a pet
|
|
$
|
631
|
|
|
$
|
591
|
|
|
$
|
591
|
|
|
$
|
619
|
|
|
$
|
557
|
|
Average pet acquisition cost
(4)
|
|
$
|
123
|
|
|
$
|
132
|
|
|
$
|
121
|
|
|
$
|
104
|
|
|
$
|
100
|
|
Average monthly retention
|
|
98.60
|
%
|
|
98.64
|
%
|
|
98.69
|
%
|
|
98.65
|
%
|
|
98.51
|
%
|
|||||
Adjusted EBITDA (in thousands)
(5)
|
|
$
|
62
|
|
|
$
|
(11,297
|
)
|
|
$
|
(10,349
|
)
|
|
$
|
(4,351
|
)
|
|
$
|
(3,904
|
)
|
|
|
As of
December 31, |
||||||||||||||||||
|
|
2016
|
|
2015
|
|
2014
|
|
2013
|
|
2012
|
||||||||||
|
|
(in thousands)
|
||||||||||||||||||
Consolidated Balance Sheet Data:
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Cash and cash equivalents
|
|
$
|
23,637
|
|
|
$
|
17,956
|
|
|
$
|
53,098
|
|
|
$
|
14,939
|
|
|
$
|
4,234
|
|
Short-term investments
|
|
29,570
|
|
|
25,288
|
|
|
22,371
|
|
|
16,088
|
|
|
10,809
|
|
|||||
Working capital
|
|
34,729
|
|
|
30,016
|
|
|
62,111
|
|
|
13,710
|
|
|
7,746
|
|
|||||
Total assets
|
|
82,345
|
|
|
70,917
|
|
|
98,306
|
|
|
51,653
|
|
|
27,666
|
|
|||||
Warrant liabilities
|
|
—
|
|
|
—
|
|
|
—
|
|
|
4,900
|
|
|
551
|
|
|||||
Current and long-term debt
|
|
4,767
|
|
|
—
|
|
|
14,900
|
|
|
26,099
|
|
|
9,900
|
|
|||||
Total liabilities
|
|
37,630
|
|
|
25,561
|
|
|
39,031
|
|
|
52,928
|
|
|
23,015
|
|
|||||
Convertible preferred stock
|
|
—
|
|
|
—
|
|
|
—
|
|
|
31,724
|
|
|
31,724
|
|
|||||
Stockholders’ equity (deficit)
|
|
44,715
|
|
|
45,356
|
|
|
59,275
|
|
|
(32,999
|
)
|
|
(27,073
|
)
|
(1)
|
Includes stock-based compensation expense as follows:
|
|
|
Years Ended December 31,
|
||||||||||||||||||
|
|
2016
|
|
2015
|
|
2014
|
|
2013
|
|
2012
|
||||||||||
|
|
(in thousands)
|
||||||||||||||||||
Cost of revenue
|
|
$
|
275
|
|
|
$
|
263
|
|
|
$
|
315
|
|
|
$
|
230
|
|
|
$
|
109
|
|
Sales and marketing
|
|
532
|
|
|
446
|
|
|
553
|
|
|
677
|
|
|
428
|
|
|||||
Technology and development
|
|
246
|
|
|
404
|
|
|
461
|
|
|
351
|
|
|
268
|
|
|||||
General and administrative
|
|
1,893
|
|
|
1,889
|
|
|
2,755
|
|
|
680
|
|
|
629
|
|
|||||
Total stock-based compensation expense
|
|
$
|
2,946
|
|
|
$
|
3,002
|
|
|
$
|
4,084
|
|
|
$
|
1,938
|
|
|
$
|
1,434
|
|
(2)
|
See note 2 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for a description of the method used to compute basic and diluted net loss per share attributable to common stockholders.
|
(3)
|
For more information about how we calculate total pets enrolled, total subscription pets enrolled, monthly average revenue per pet, lifetime value of a pet, average pet acquisition cost and average monthly retention, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Key Financial and Operating Metrics.”
|
(4)
|
Average pet acquisition cost is calculated in part based on acquisition cost and net acquisition cost, non-GAAP financial measures. Acquisition cost is defined as sales and marketing expenses, excluding stock-based compensation expense. Net acquisition cost is defined as acquisition cost, net of sign-up fee revenue and other business segment sales and marketing expense. For more information about acquisition cost, net acquisition cost and a reconciliation of sales and marketing expenses to acquisition cost and net acquisition cost, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Non-GAAP Financial Measures.”
|
(5)
|
Adjusted EBITDA is a non-GAAP financial measure that we define as net loss excluding stock-based compensation expense, depreciation and amortization expense, interest income, interest expense, change in fair value of warrant liabilities, income tax expense (benefit) and loss (income) from equity method investment. For more information about Adjusted EBITDA, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Non-GAAP Financial Measures.”
|
|
|
Years Ended December 31,
|
||||||||||
|
|
2016
|
|
2015
|
|
2014
|
||||||
Total pets enrolled (at period end)
|
|
343,649
|
|
|
291,818
|
|
|
232,450
|
|
|||
Total subscription pets enrolled (at period end)
|
|
323,233
|
|
|
272,636
|
|
|
215,491
|
|
|||
Monthly average revenue per pet
|
|
$
|
47.82
|
|
|
$
|
45.04
|
|
|
$
|
44.14
|
|
Lifetime value of a pet (LVP)
|
|
$
|
631
|
|
|
$
|
591
|
|
|
$
|
591
|
|
Average pet acquisition cost (PAC)
|
|
$
|
123
|
|
|
$
|
132
|
|
|
$
|
121
|
|
Average monthly retention
|
|
98.60
|
%
|
|
98.64
|
%
|
|
98.69
|
%
|
|||
Adjusted EBITDA (in thousands)
|
|
$
|
62
|
|
|
$
|
(11,297
|
)
|
|
$
|
(10,349
|
)
|
|
Period Ended
|
||||||||||||||||||||||||||||||
|
Dec. 31, 2016
|
|
Sept. 30, 2016
|
|
Jun. 30, 2016
|
|
Mar. 31, 2016
|
|
Dec. 31, 2015
|
|
Sept. 30, 2015
|
|
Jun. 30, 2015
|
|
Mar. 31, 2015
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Total pets enrolled (at period end)
|
343,649
|
|
|
334,070
|
|
|
320,896
|
|
|
307,298
|
|
|
291,818
|
|
|
276,988
|
|
|
259,948
|
|
|
246,106
|
|
||||||||
Total subscription pets enrolled (at period end)
|
323,233
|
|
|
312,282
|
|
|
299,856
|
|
|
287,123
|
|
|
272,636
|
|
|
258,546
|
|
|
241,808
|
|
|
228,409
|
|
||||||||
Monthly average revenue per pet
|
$
|
49.17
|
|
|
$
|
48.37
|
|
|
$
|
47.39
|
|
|
$
|
46.12
|
|
|
$
|
45.48
|
|
|
$
|
45.15
|
|
|
$
|
45.10
|
|
|
$
|
44.34
|
|
Lifetime value of a pet (LVP)
|
$
|
631
|
|
|
$
|
624
|
|
|
$
|
622
|
|
|
$
|
603
|
|
|
$
|
591
|
|
|
$
|
591
|
|
|
$
|
570
|
|
|
$
|
567
|
|
Average pet acquisition cost (PAC)
|
$
|
133
|
|
|
$
|
120
|
|
|
$
|
118
|
|
|
$
|
123
|
|
|
$
|
132
|
|
|
$
|
129
|
|
|
$
|
133
|
|
|
$
|
134
|
|
Average monthly retention
|
98.60
|
%
|
|
98.61
|
%
|
|
98.64
|
%
|
|
98.65
|
%
|
|
98.64
|
%
|
|
98.66
|
%
|
|
98.67
|
%
|
|
98.66
|
%
|
||||||||
Adjusted EBITDA (in thousands)
|
$
|
302
|
|
|
$
|
304
|
|
|
$
|
522
|
|
|
$
|
(1,066
|
)
|
|
$
|
(1,588
|
)
|
|
$
|
(3,211
|
)
|
|
$
|
(3,165
|
)
|
|
$
|
(3,333
|
)
|
|
|
Years Ended December 31,
|
||||||||||
|
|
2016
|
|
2015
|
|
2014
|
||||||
|
|
(in thousands)
|
||||||||||
Sales and marketing expenses
|
|
$
|
15,247
|
|
|
$
|
15,231
|
|
|
$
|
11,608
|
|
Excluding:
|
|
|
|
|
|
|
||||||
Stock-based compensation expense
|
|
(532
|
)
|
|
(446
|
)
|
|
(553
|
)
|
|||
Acquisition cost
|
|
14,715
|
|
|
14,785
|
|
|
11,055
|
|
|||
Net of:
|
|
|
|
|
|
|
||||||
Sign-up fee revenue
|
|
(2,073
|
)
|
|
(1,983
|
)
|
|
(1,572
|
)
|
|||
Other business segment sales and marketing expense
|
|
(218
|
)
|
|
(80
|
)
|
|
(124
|
)
|
|||
Net acquisition cost
|
|
$
|
12,424
|
|
|
$
|
12,722
|
|
|
$
|
9,359
|
|
|
Three Months Ended
|
||||||||||||||||||||||||||||||
|
Dec. 31, 2016
|
|
Sept. 30, 2016
|
|
Jun. 30, 2016
|
|
Mar. 31, 2016
|
|
Dec. 31, 2015
|
|
Sept. 30, 2015
|
|
Jun. 30, 2015
|
|
Mar. 31, 2015
|
||||||||||||||||
|
(in thousands)
|
||||||||||||||||||||||||||||||
Sales and marketing expenses
|
$
|
3,951
|
|
|
$
|
3,892
|
|
|
$
|
3,564
|
|
|
$
|
3,840
|
|
|
$
|
3,919
|
|
|
$
|
4,128
|
|
|
$
|
3,533
|
|
|
$
|
3,651
|
|
Excluding:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Stock-based compensation expense
|
(113
|
)
|
|
(172
|
)
|
|
(165
|
)
|
|
(82
|
)
|
|
(104
|
)
|
|
(102
|
)
|
|
(110
|
)
|
|
(130
|
)
|
||||||||
Acquisition cost
|
3,838
|
|
|
3,720
|
|
|
3,399
|
|
|
3,758
|
|
|
3,815
|
|
|
4,026
|
|
|
3,423
|
|
|
3,521
|
|
||||||||
Net of:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Sign-up fee revenue
|
(526
|
)
|
|
(525
|
)
|
|
(495
|
)
|
|
(527
|
)
|
|
(506
|
)
|
|
(542
|
)
|
|
(451
|
)
|
|
(484
|
)
|
||||||||
Other business segment sales and marketing expense
|
(62
|
)
|
|
(63
|
)
|
|
(55
|
)
|
|
(38
|
)
|
|
(8
|
)
|
|
(16
|
)
|
|
(30
|
)
|
|
(26
|
)
|
||||||||
Net acquisition cost
|
$
|
3,250
|
|
|
$
|
3,132
|
|
|
$
|
2,849
|
|
|
$
|
3,193
|
|
|
$
|
3,301
|
|
|
$
|
3,468
|
|
|
$
|
2,942
|
|
|
$
|
3,011
|
|
|
|
Years Ended December 31,
|
||||||||||
|
|
2016
|
|
2015
|
|
2014
|
||||||
|
|
(in thousands)
|
||||||||||
Net loss
|
|
$
|
(6,896
|
)
|
|
$
|
(17,205
|
)
|
|
$
|
(21,177
|
)
|
Excluding:
|
|
|
|
|
|
|
||||||
Stock-based compensation expense
|
|
2,946
|
|
|
3,002
|
|
|
4,084
|
|
|||
Depreciation and amortization expense
|
|
3,846
|
|
|
2,542
|
|
|
1,675
|
|
|||
Interest income
|
|
(119
|
)
|
|
(75
|
)
|
|
(74
|
)
|
|||
Interest expense
|
|
218
|
|
|
325
|
|
|
6,726
|
|
|||
Change in fair value of warrant liabilities
|
|
—
|
|
|
—
|
|
|
(1,575
|
)
|
|||
Income tax expense (benefit)
|
|
38
|
|
|
114
|
|
|
(8
|
)
|
|||
Loss (income) from equity method investment
|
|
29
|
|
|
—
|
|
|
—
|
|
|||
Adjusted EBITDA
|
|
$
|
62
|
|
|
$
|
(11,297
|
)
|
|
$
|
(10,349
|
)
|
|
Three Months Ended
|
||||||||||||||||||||||||||||||
|
Dec. 31, 2016
|
|
Sept. 30, 2016
|
|
Jun. 30, 2016
|
|
Mar. 31, 2016
|
|
Dec. 31, 2015
|
|
Sept. 30, 2015
|
|
Jun. 30, 2015
|
|
Mar. 31, 2015
|
||||||||||||||||
|
(in thousands)
|
||||||||||||||||||||||||||||||
Net loss
|
$
|
(1,723
|
)
|
|
$
|
(1,637
|
)
|
|
$
|
(964
|
)
|
|
$
|
(2,572
|
)
|
|
$
|
(3,001
|
)
|
|
$
|
(4,643
|
)
|
|
$
|
(4,625
|
)
|
|
$
|
(4,936
|
)
|
Excluding:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Stock-based compensation expense
|
731
|
|
|
776
|
|
|
743
|
|
|
696
|
|
|
653
|
|
|
749
|
|
|
897
|
|
|
703
|
|
||||||||
Depreciation and amortization expense
|
1,229
|
|
|
1,093
|
|
|
739
|
|
|
785
|
|
|
741
|
|
|
672
|
|
|
563
|
|
|
566
|
|
||||||||
Interest income
|
(41
|
)
|
|
(29
|
)
|
|
(26
|
)
|
|
(23
|
)
|
|
(19
|
)
|
|
(19
|
)
|
|
(18
|
)
|
|
(19
|
)
|
||||||||
Interest expense
|
81
|
|
|
66
|
|
|
41
|
|
|
30
|
|
|
26
|
|
|
14
|
|
|
40
|
|
|
245
|
|
||||||||
Income tax expense(benefit)
|
7
|
|
|
13
|
|
|
4
|
|
|
14
|
|
|
12
|
|
|
16
|
|
|
(22
|
)
|
|
108
|
|
||||||||
Loss (income) from equity method investment
|
18
|
|
|
22
|
|
|
(15
|
)
|
|
4
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
Adjusted EBITDA
|
$
|
302
|
|
|
$
|
304
|
|
|
$
|
522
|
|
|
$
|
(1,066
|
)
|
|
$
|
(1,588
|
)
|
|
$
|
(3,211
|
)
|
|
$
|
(3,165
|
)
|
|
$
|
(3,333
|
)
|
|
Years Ended December 31,
|
||||||||||
|
2016
|
|
2015
|
|
2014
|
||||||
|
(in thousands)
|
||||||||||
Consolidated Statements of Operations Data:
|
|
|
|
|
|
||||||
Revenue:
|
|
|
|
|
|
||||||
Subscription business
|
$
|
173,356
|
|
|
$
|
133,406
|
|
|
$
|
103,502
|
|
Other business
|
14,874
|
|
|
13,557
|
|
|
12,408
|
|
|||
Total revenue
|
188,230
|
|
|
146,963
|
|
|
115,910
|
|
|||
Cost of revenue:
|
|
|
|
|
|
||||||
Subscription business
(1)
|
141,321
|
|
|
109,428
|
|
|
85,169
|
|
|||
Other business
|
13,621
|
|
|
12,306
|
|
|
10,867
|
|
|||
Total cost of revenue
|
154,942
|
|
|
121,734
|
|
|
96,036
|
|
|||
Gross profit:
|
|
|
|
|
|
||||||
Subscription business
|
32,035
|
|
|
23,978
|
|
|
18,333
|
|
|||
Other business
|
1,253
|
|
|
1,251
|
|
|
1,541
|
|
|||
Total gross profit
|
33,288
|
|
|
25,229
|
|
|
19,874
|
|
|||
Operating expenses:
|
|
|
|
|
|
||||||
Sales and marketing
(1)
|
15,247
|
|
|
15,231
|
|
|
11,608
|
|
|||
Technology and development
(1)
|
9,534
|
|
|
11,215
|
|
|
9,899
|
|
|||
General and administrative
(1)
|
15,205
|
|
|
15,558
|
|
|
14,312
|
|
|||
Total operating expenses
|
39,986
|
|
|
42,004
|
|
|
35,819
|
|
|||
Operating loss
|
(6,698
|
)
|
|
(16,775
|
)
|
|
(15,945
|
)
|
|||
Interest expense
|
218
|
|
|
325
|
|
|
6,726
|
|
|||
Other income, net
|
(58
|
)
|
|
(9
|
)
|
|
(1,487
|
)
|
|||
Loss before income taxes
|
(6,858
|
)
|
|
(17,091
|
)
|
|
(21,184
|
)
|
|||
Income tax expense (benefit)
|
38
|
|
|
114
|
|
|
(7
|
)
|
|||
Net loss
|
$
|
(6,896
|
)
|
|
$
|
(17,205
|
)
|
|
$
|
(21,177
|
)
|
(1)
|
Includes stock-based compensation expense as follows:
|
|
Years Ended December 31,
|
||||||||||
|
2016
|
|
2015
|
|
2014
|
||||||
|
(in thousands)
|
||||||||||
Cost of revenue
|
$
|
275
|
|
|
$
|
263
|
|
|
$
|
315
|
|
Sales and marketing
|
532
|
|
|
446
|
|
|
553
|
|
|||
Technology and development
|
246
|
|
|
404
|
|
|
461
|
|
|||
General and administrative
|
1,893
|
|
|
1,889
|
|
|
2,755
|
|
|||
Total stock-based compensation expense
|
$
|
2,946
|
|
|
$
|
3,002
|
|
|
$
|
4,084
|
|
|
Years Ended December 31,
|
|||||||
|
2016
|
|
2015
|
|
2014
|
|||
Subscription business revenue
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
Subscription business cost of revenue
|
82
|
|
|
82
|
|
|
82
|
|
Subscription business gross profit
|
18
|
%
|
|
18
|
%
|
|
18
|
%
|
|
Years Ended December 31,
|
|
2015 to 2016 % Change
|
|
2014 to 2015 % Change
|
||||||||||
|
2016
|
|
2015
|
|
2014
|
|
|
||||||||
|
(in thousands, except percentages, pet and per pet data)
|
|
|
|
|
||||||||||
Revenue:
|
|
|
|
|
|
|
|
|
|
||||||
Subscription business
|
$
|
173,356
|
|
|
$
|
133,406
|
|
|
$
|
103,502
|
|
|
30%
|
|
29%
|
Other business
|
14,874
|
|
|
13,557
|
|
|
12,408
|
|
|
10
|
|
9
|
|||
Total revenue
|
$
|
188,230
|
|
|
$
|
146,963
|
|
|
$
|
115,910
|
|
|
28
|
|
27
|
Percentage of Revenue by Segment:
|
|
|
|
|
|
|
|
|
|
||||||
Subscription business
|
92
|
%
|
|
91
|
%
|
|
89
|
%
|
|
|
|
|
|||
Other business
|
8
|
|
|
9
|
|
|
11
|
|
|
|
|
|
|||
Total revenue
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
||||||
Total pets enrolled (at period end)
|
343,649
|
|
|
291,818
|
|
|
232,450
|
|
|
18
|
|
26
|
|||
Total subscription pets enrolled (at period end)
|
323,233
|
|
|
272,636
|
|
|
215,491
|
|
|
19
|
|
27
|
|||
Monthly average revenue per pet
|
$
|
47.82
|
|
|
$
|
45.04
|
|
|
$
|
44.14
|
|
|
6
|
|
2
|
Average monthly retention
|
98.60
|
%
|
|
98.64
|
%
|
|
98.69
|
%
|
|
|
|
|
|
Years Ended December 31,
|
|
2015 to 2016 % Change
|
|
2014 to 2015 % Change
|
||||||||||
|
2016
|
|
2015
|
|
2014
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
||||||
|
(in thousands, except percentages)
|
|
|
|
|
||||||||||
Cost of Revenue:
|
|
|
|
|
|
|
|
|
|
||||||
Subscription business:
|
|
|
|
|
|
|
|
|
|
||||||
Claims expenses
|
$
|
124,636
|
|
|
$
|
95,420
|
|
|
$
|
74,206
|
|
|
31%
|
|
29%
|
Other cost of revenue
|
16,685
|
|
|
14,008
|
|
|
10,963
|
|
|
19
|
|
28
|
|||
Total cost of revenue
|
141,321
|
|
|
109,428
|
|
|
85,169
|
|
|
29
|
|
28
|
|||
Gross profit
|
32,035
|
|
|
23,978
|
|
|
18,333
|
|
|
34
|
|
31
|
|||
Other business:
|
|
|
|
|
|
|
|
|
|
||||||
Claims expenses
|
8,898
|
|
|
7,904
|
|
|
5,707
|
|
|
13
|
|
38
|
|||
Other cost of revenue
|
4,723
|
|
|
4,402
|
|
|
5,160
|
|
|
7
|
|
(15)
|
|||
Total cost of revenue
|
13,621
|
|
|
12,306
|
|
|
10,867
|
|
|
11
|
|
13
|
|||
Gross profit
|
1,253
|
|
|
1,251
|
|
|
1,541
|
|
|
—
|
|
(19)
|
|||
Total pets enrolled (at period end)
|
343,649
|
|
|
291,818
|
|
|
232,450
|
|
|
18
|
|
26
|
|||
Total subscription pets enrolled (at period end)
|
323,233
|
|
|
272,636
|
|
|
215,491
|
|
|
19
|
|
27
|
|||
Percentage of Revenue by Segment:
|
|
|
|
|
|
|
|
|
|
||||||
Subscription business:
|
|
|
|
|
|
|
|
|
|
||||||
Claims expenses
|
72
|
%
|
|
72
|
%
|
|
72
|
%
|
|
|
|
|
|||
Other cost of revenue
|
10
|
|
|
10
|
|
|
10
|
|
|
|
|
|
|||
Total cost of revenue
|
82
|
|
|
82
|
|
|
82
|
|
|
|
|
|
|||
Gross profit
|
18
|
|
|
18
|
|
|
18
|
|
|
|
|
|
|||
Other business:
|
|
|
|
|
|
|
|
|
|
||||||
Claims expenses
|
60
|
|
|
58
|
|
|
46
|
|
|
|
|
|
|||
Other cost of revenue
|
32
|
|
|
32
|
|
|
42
|
|
|
|
|
|
|||
Total cost of revenue
|
92
|
|
|
91
|
|
|
88
|
|
|
|
|
|
|||
Gross profit
|
8
|
|
|
9
|
|
|
12
|
|
|
|
|
|
|
Years Ended December 31,
|
|
2015 to 2016 % Change
|
|
2014 to 2015 % Change
|
||||||||||
|
2016
|
|
2015
|
|
2014
|
|
|
||||||||
|
(in thousands, except percentages and per pet data)
|
|
|
|
|
||||||||||
Sales and marketing
|
$
|
15,247
|
|
|
$
|
15,231
|
|
|
$
|
11,608
|
|
|
—%
|
|
31%
|
Percentage of total revenue
|
8
|
%
|
|
10
|
%
|
|
10
|
%
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
||||||
Subscription Business:
|
|
|
|
|
|
|
|
|
|
||||||
Total subscription pets enrolled (at period end)
|
323,233
|
|
|
272,636
|
|
|
215,491
|
|
|
19
|
|
27
|
|||
Average pet acquisition cost (PAC)
|
$
|
123
|
|
|
$
|
132
|
|
|
$
|
121
|
|
|
(7)
|
|
9
|
Lifetime Value of a Pet (LVP)
|
$
|
631
|
|
|
$
|
591
|
|
|
$
|
591
|
|
|
7
|
|
—
|
|
|
Years Ended December 31,
|
|
2015 to 2016 % Change
|
|
2014 to 2015 % Change
|
||||||||||
|
|
2016
|
|
2015
|
|
2014
|
|
|
||||||||
|
|
(in thousands, except percentages)
|
|
|
|
|
||||||||||
General and administrative
|
|
$
|
15,205
|
|
|
$
|
15,558
|
|
|
$
|
14,312
|
|
|
(2)%
|
|
9%
|
Percentage of total revenue
|
|
8
|
%
|
|
11
|
%
|
|
12
|
%
|
|
|
|
|
|
|
Years Ended December 31,
|
||||||||||
|
|
2016
|
|
2015
|
|
2014
|
||||||
|
|
|
|
|
|
|
||||||
|
|
(in thousands)
|
||||||||||
Interest expense
|
|
$
|
218
|
|
|
$
|
325
|
|
|
$
|
6,726
|
|
Other income, net
|
|
(58
|
)
|
|
(9
|
)
|
|
(1,487
|
)
|
|||
Total other expense, net
|
|
$
|
160
|
|
|
$
|
316
|
|
|
$
|
5,239
|
|
|
Three Months Ended
|
||||||||||||||||||||||||||||||
|
Dec. 31, 2016
|
|
Sept. 30, 2016
|
|
Jun. 30, 2016
|
|
Mar. 31, 2016
|
|
Dec. 31, 2015
|
|
Sept. 30, 2015
|
|
Jun. 30, 2015
|
|
Mar. 31, 2015
|
||||||||||||||||
|
(in thousands)
|
||||||||||||||||||||||||||||||
Consolidated Statements of Operations Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Subscription business
|
$
|
47,422
|
|
|
$
|
44,629
|
|
|
$
|
42,162
|
|
|
$
|
39,143
|
|
|
$
|
36,722
|
|
|
$
|
34,420
|
|
|
$
|
32,208
|
|
|
$
|
30,056
|
|
Other business
|
3,918
|
|
|
3,730
|
|
|
3,670
|
|
|
3,556
|
|
|
3,479
|
|
|
3,445
|
|
|
3,379
|
|
|
3,254
|
|
||||||||
Total revenue
|
51,340
|
|
|
48,359
|
|
|
45,832
|
|
|
42,699
|
|
|
40,201
|
|
|
37,865
|
|
|
35,587
|
|
|
33,310
|
|
||||||||
Cost of revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Subscription business
(1)
|
38,528
|
|
|
36,432
|
|
|
34,158
|
|
|
32,203
|
|
|
29,856
|
|
|
28,146
|
|
|
26,661
|
|
|
24,766
|
|
||||||||
Other business
|
3,594
|
|
|
3,427
|
|
|
3,408
|
|
|
3,192
|
|
|
3,075
|
|
|
3,128
|
|
|
3,140
|
|
|
2,962
|
|
||||||||
Total cost of revenue
|
42,122
|
|
|
39,859
|
|
|
37,566
|
|
|
35,395
|
|
|
32,931
|
|
|
31,274
|
|
|
29,801
|
|
|
27,728
|
|
||||||||
Gross profit:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Subscription business
|
8,894
|
|
|
8,197
|
|
|
8,004
|
|
|
6,940
|
|
|
6,866
|
|
|
6,274
|
|
|
5,547
|
|
|
5,290
|
|
||||||||
Other business
|
324
|
|
|
303
|
|
|
262
|
|
|
364
|
|
|
404
|
|
|
317
|
|
|
239
|
|
|
292
|
|
||||||||
Total gross profit
|
9,218
|
|
|
8,500
|
|
|
8,266
|
|
|
7,304
|
|
|
7,270
|
|
|
6,591
|
|
|
5,786
|
|
|
5,582
|
|
||||||||
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Sales and marketing
(1)
|
3,951
|
|
|
3,892
|
|
|
3,564
|
|
|
3,840
|
|
|
3,919
|
|
|
4,128
|
|
|
3,533
|
|
|
3,651
|
|
||||||||
Technology and development
(1)
|
2,744
|
|
|
2,339
|
|
|
2,164
|
|
|
2,287
|
|
|
2,533
|
|
|
3,005
|
|
|
2,879
|
|
|
2,798
|
|
||||||||
General and administrative
(1)
|
4,177
|
|
|
3,811
|
|
|
3,495
|
|
|
3,722
|
|
|
3,798
|
|
|
4,067
|
|
|
3,996
|
|
|
3,697
|
|
||||||||
Total operating expenses
|
10,872
|
|
|
10,042
|
|
|
9,223
|
|
|
9,849
|
|
|
10,250
|
|
|
11,200
|
|
|
10,408
|
|
|
10,146
|
|
||||||||
Operating loss
|
(1,654
|
)
|
|
(1,542
|
)
|
|
(957
|
)
|
|
(2,545
|
)
|
|
(2,980
|
)
|
|
(4,609
|
)
|
|
(4,622
|
)
|
|
(4,564
|
)
|
||||||||
Interest expense
|
81
|
|
|
66
|
|
|
41
|
|
|
30
|
|
|
26
|
|
|
14
|
|
|
40
|
|
|
245
|
|
||||||||
Other (income) expense, net
|
(19
|
)
|
|
16
|
|
|
(38
|
)
|
|
(17
|
)
|
|
(17
|
)
|
|
4
|
|
|
(15
|
)
|
|
19
|
|
||||||||
Loss before income taxes
|
(1,716
|
)
|
|
(1,624
|
)
|
|
(960
|
)
|
|
(2,558
|
)
|
|
(2,989
|
)
|
|
(4,627
|
)
|
|
(4,647
|
)
|
|
(4,828
|
)
|
||||||||
Income tax expense (benefit)
|
7
|
|
|
13
|
|
|
4
|
|
|
14
|
|
|
12
|
|
|
16
|
|
|
(22
|
)
|
|
108
|
|
||||||||
Net loss
|
$
|
(1,723
|
)
|
|
$
|
(1,637
|
)
|
|
$
|
(964
|
)
|
|
$
|
(2,572
|
)
|
|
$
|
(3,001
|
)
|
|
$
|
(4,643
|
)
|
|
$
|
(4,625
|
)
|
|
$
|
(4,936
|
)
|
|
Period Ended
|
||||||||||||||||||||||||||||||
|
Dec. 31, 2016
|
|
Sept. 30, 2016
|
|
Jun. 30, 2016
|
|
Mar. 31, 2016
|
|
Dec. 31, 2015
|
|
Sept. 30, 2015
|
|
Jun. 30, 2015
|
|
Mar. 31, 2015
|
||||||||||||||||
Other Financial and Operational Data
(2)
:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Total pets enrolled
|
343,649
|
|
|
334,070
|
|
|
320,896
|
|
|
307,298
|
|
|
291,818
|
|
|
276,988
|
|
|
259,948
|
|
|
246,106
|
|
||||||||
Total subscription pets enrolled
|
323,233
|
|
|
312,282
|
|
|
299,856
|
|
|
287,123
|
|
|
272,636
|
|
|
258,546
|
|
|
241,808
|
|
|
228,409
|
|
||||||||
Monthly average revenue per pet
|
$
|
49.17
|
|
|
$
|
48.37
|
|
|
$
|
47.39
|
|
|
$
|
46.12
|
|
|
$
|
45.48
|
|
|
$
|
45.15
|
|
|
$
|
45.10
|
|
|
$
|
44.34
|
|
Lifetime value of a pet
|
$
|
631
|
|
|
$
|
624
|
|
|
$
|
622
|
|
|
$
|
603
|
|
|
$
|
591
|
|
|
$
|
591
|
|
|
$
|
570
|
|
|
$
|
567
|
|
Average pet acquisition cost
(3)
|
$
|
133
|
|
|
$
|
120
|
|
|
$
|
118
|
|
|
$
|
123
|
|
|
$
|
132
|
|
|
$
|
129
|
|
|
$
|
133
|
|
|
$
|
134
|
|
Average monthly retention
|
98.60
|
%
|
|
98.61
|
%
|
|
98.64
|
%
|
|
98.65
|
%
|
|
98.64
|
%
|
|
98.66
|
%
|
|
98.67
|
%
|
|
98.66
|
%
|
||||||||
Adjusted EBITDA (in thousands)
(4)
|
$
|
302
|
|
|
$
|
304
|
|
|
$
|
522
|
|
|
$
|
(1,066
|
)
|
|
$
|
(1,588
|
)
|
|
$
|
(3,211
|
)
|
|
$
|
(3,165
|
)
|
|
$
|
(3,333
|
)
|
|
Three Months Ended
|
||||||||||||||||||||||||||||||
|
Dec. 31, 2016
|
|
Sept. 30, 2016
|
|
Jun. 30, 2016
|
|
Mar. 31, 2016
|
|
Dec. 31, 2015
|
|
Sept. 30, 2015
|
|
Jun. 30, 2015
|
|
Mar. 31, 2015
|
||||||||||||||||
|
(in thousands)
|
||||||||||||||||||||||||||||||
Cost of revenue
|
$
|
60
|
|
|
$
|
83
|
|
|
$
|
66
|
|
|
$
|
66
|
|
|
$
|
68
|
|
|
$
|
68
|
|
|
$
|
58
|
|
|
$
|
69
|
|
Sales and marketing
|
113
|
|
|
172
|
|
|
165
|
|
|
82
|
|
|
104
|
|
|
102
|
|
|
110
|
|
|
130
|
|
||||||||
Technology and development
|
88
|
|
|
67
|
|
|
36
|
|
|
55
|
|
|
93
|
|
|
97
|
|
|
93
|
|
|
121
|
|
||||||||
General and administrative
|
470
|
|
|
454
|
|
|
476
|
|
|
493
|
|
|
388
|
|
|
482
|
|
|
636
|
|
|
383
|
|
(2)
|
For more information about how we calculate total pets enrolled, total subscription pets enrolled, monthly average revenue per pet, lifetime value of a pet, average pet acquisition cost and average monthly retention, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Key Financial and Operating Metrics.”
|
(3)
|
Average pet acquisition cost is calculated in part based on acquisition cost and net acquisition cost, non-GAAP financial measures. Acquisition cost is defined as sales and marketing expenses, excluding stock-based compensation expense. Net acquisition cost is defined as acquisition cost, net of sign-up fee revenue and other business segment sales and marketing expense. For more information about acquisition cost, net acquisition cost and a reconciliation of sales and marketing expenses to acquisition cost and net acquisition cost, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Non-GAAP Financial Measures.”
|
(4)
|
Adjusted EBITDA is a non-GAAP financial measure that we define as net loss excluding stock-based compensation expense, depreciation and amortization expense, interest income, interest expense, change in fair value of warrant liabilities, income tax expense (benefit) and loss (income) from equity method investment. For more information about Adjusted EBITDA, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Non-GAAP Financial Measures.”
|
|
Three Months Ended
|
||||||||||||||||||||||
|
Dec. 31, 2016
|
|
Sept. 30, 2016
|
|
Jun. 30, 2016
|
|
Mar. 31, 2016
|
|
Dec. 31, 2015
|
|
Sept. 30, 2015
|
|
Jun. 30, 2015
|
|
Mar. 31, 2015
|
||||||||
|
(as a percentage of revenue)
|
||||||||||||||||||||||
Revenue
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
Cost of revenue
|
82
|
|
|
82
|
|
|
82
|
|
|
83
|
|
|
82
|
|
|
83
|
|
|
84
|
|
|
83
|
|
Gross profit
|
18
|
|
|
18
|
|
|
18
|
|
|
17
|
|
|
18
|
|
|
17
|
|
|
16
|
|
|
17
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Sales and marketing
|
8
|
|
|
8
|
|
|
8
|
|
|
9
|
|
|
10
|
|
|
11
|
|
|
10
|
|
|
11
|
|
Technology and development
|
5
|
|
|
5
|
|
|
5
|
|
|
5
|
|
|
6
|
|
|
8
|
|
|
8
|
|
|
8
|
|
General and administrative
|
8
|
|
|
8
|
|
|
8
|
|
|
9
|
|
|
9
|
|
|
11
|
|
|
11
|
|
|
11
|
|
Total operating expenses
|
21
|
|
|
21
|
|
|
20
|
|
|
23
|
|
|
25
|
|
|
30
|
|
|
29
|
|
|
30
|
|
Operating loss
|
(3
|
)
|
|
(3
|
)
|
|
(2
|
)
|
|
(6
|
)
|
|
(7
|
)
|
|
(12
|
)
|
|
(13
|
)
|
|
(14
|
)
|
Interest expense
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1
|
)
|
Other (income) expense, net
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
Loss before income taxes
|
(3
|
)
|
|
(3
|
)
|
|
(2
|
)
|
|
(6
|
)
|
|
(7
|
)
|
|
(12
|
)
|
|
(13
|
)
|
|
(15
|
)
|
Income tax expense (benefit)
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
Net loss
|
(3
|
)%
|
|
(3
|
)%
|
|
(2
|
)%
|
|
(6
|
)%
|
|
(7
|
)%
|
|
(12
|
)%
|
|
(13
|
)%
|
|
(15
|
)%
|
|
Three Months Ended
|
||||||||||||||||||||||
|
Dec. 31, 2016
|
|
Sept. 30, 2016
|
|
Jun. 30, 2016
|
|
Mar. 31, 2016
|
|
Dec. 31, 2015
|
|
Sept. 30, 2015
|
|
Jun. 30, 2015
|
|
Mar. 31, 2015
|
||||||||
|
(as a percentage of subscription revenue)
|
||||||||||||||||||||||
Subscription business revenue
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
Subscription business cost of revenue
|
81
|
|
|
82
|
|
|
81
|
|
|
82
|
|
|
81
|
|
|
82
|
|
|
83
|
|
|
82
|
|
Subscription business gross profit
|
19
|
%
|
|
18
|
%
|
|
19
|
%
|
|
18
|
%
|
|
19
|
%
|
|
18
|
%
|
|
17
|
%
|
|
18
|
%
|
|
Years Ended December 31,
|
||||||||||
|
2016
|
|
2015
|
|
2014
|
||||||
Net cash provided by (used in) operating activities
|
$
|
5,006
|
|
|
$
|
(10,425
|
)
|
|
$
|
(10,801
|
)
|
Net cash used in investing activities
|
(6,508
|
)
|
|
(9,923
|
)
|
|
(11,926
|
)
|
|||
Net cash provided by (used in) financing activities
|
7,672
|
|
|
(14,208
|
)
|
|
57,863
|
|
|||
Effect of exchange rates on cash
|
111
|
|
|
(586
|
)
|
|
23
|
|
|||
Net change in cash, cash equivalents, and restricted cash
|
$
|
6,281
|
|
|
$
|
(35,142
|
)
|
|
$
|
35,159
|
|
|
|
Total
|
|
Less Than
1 Year
|
|
1-3 Years
|
|
3-5 Years
|
|
More Than
5 Years
|
||||||||||
Long-term debt obligations
|
|
$
|
5,450
|
|
|
$
|
225
|
|
|
$
|
5,225
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Capital lease obligations
|
|
581
|
|
|
374
|
|
|
207
|
|
|
—
|
|
|
—
|
|
|||||
Operating lease obligations
|
|
20,702
|
|
|
1,510
|
|
|
3,880
|
|
|
4,283
|
|
|
11,029
|
|
|||||
Strategic marketing and service provider agreements
|
|
2,450
|
|
|
1,269
|
|
|
1,114
|
|
|
67
|
|
|
—
|
|
|||||
Other obligations
|
|
3,755
|
|
|
2,355
|
|
|
1,331
|
|
|
69
|
|
|
—
|
|
•
|
stock-based compensation;
|
•
|
income taxes; and
|
•
|
claims reserve.
|
•
|
Expected volatility
—As we do not have a significant trading history for our common stock, the expected stock price volatility for our common stock was estimated by taking the average historic price volatility for identified peers based on daily price observations over a period equivalent to the expected term of the stock option grants and warrant
|
•
|
Expected term
—The expected term represents the period that our stock-based awards are expected to be outstanding. As we do not have sufficient historical experience for determining the expected term of the stock-based awards granted, we have based our expected term for awards issued to employees on the simplified method, which represents the average period from vesting to the expiration of the stock option.
|
•
|
Risk-free interest rate
—The risk-free interest rate is based on the yields of U.S. Treasury securities with maturities similar to the expected term of the options.
|
•
|
Expected dividend yield
—We have never declared or paid any cash dividends and do not presently plan to pay cash dividends in the foreseeable future. Consequently, we used an expected dividend yield of zero.
|
|
Page
|
Trupanion, Inc.
Consolidated Statements of Operations
(in thousands, except for share and per share data)
|
|||||||||||
|
Years Ended December 31,
|
||||||||||
|
2016
|
|
2015
|
|
2014
|
||||||
Revenue
|
$
|
188,230
|
|
|
$
|
146,963
|
|
|
$
|
115,910
|
|
Cost of revenue:
|
|
|
|
|
|
||||||
Claims expenses
|
133,534
|
|
|
103,324
|
|
|
79,913
|
|
|||
Other cost of revenue
|
21,408
|
|
|
18,410
|
|
|
16,123
|
|
|||
Gross profit
|
33,288
|
|
|
25,229
|
|
|
19,874
|
|
|||
Operating expenses:
|
|
|
|
|
|
||||||
Sales and marketing
|
15,247
|
|
|
15,231
|
|
|
11,608
|
|
|||
Technology and development
|
9,534
|
|
|
11,215
|
|
|
9,899
|
|
|||
General and administrative
|
15,205
|
|
|
15,558
|
|
|
14,312
|
|
|||
Total operating expenses
|
39,986
|
|
|
42,004
|
|
|
35,819
|
|
|||
Operating loss
|
(6,698
|
)
|
|
(16,775
|
)
|
|
(15,945
|
)
|
|||
Interest expense
|
218
|
|
|
325
|
|
|
6,726
|
|
|||
Other income, net
|
(58
|
)
|
|
(9
|
)
|
|
(1,487
|
)
|
|||
Loss before income taxes
|
(6,858
|
)
|
|
(17,091
|
)
|
|
(21,184
|
)
|
|||
Income tax expense (benefit)
|
38
|
|
|
114
|
|
|
(7
|
)
|
|||
Net loss
|
$
|
(6,896
|
)
|
|
$
|
(17,205
|
)
|
|
$
|
(21,177
|
)
|
|
|
|
|
|
|
||||||
Net loss per share attributable to common stockholders:
|
|
|
|
|
|
||||||
Basic and diluted
|
$
|
(0.24
|
)
|
|
$
|
(0.62
|
)
|
|
$
|
(1.64
|
)
|
Weighted average shares used to compute net loss per share attributable to common stockholders:
|
|
|
|
|
|
||||||
Basic and diluted
|
28,527,602
|
|
27,638,443
|
|
12,934,477
|
Trupanion, Inc.
Consolidated Statements of Comprehensive Loss
(in thousands)
|
|||||||||||
|
Years Ended December 31,
|
||||||||||
|
|||||||||||
|
2016
|
|
2015
|
|
2014
|
||||||
Net loss
|
$
|
(6,896
|
)
|
|
$
|
(17,205
|
)
|
|
$
|
(21,177
|
)
|
Other comprehensive income (loss):
|
|
|
|
|
|
||||||
Foreign currency translation adjustments
|
79
|
|
|
(517
|
)
|
|
65
|
|
|||
Change in unrealized losses on available-for-sale securities
|
46
|
|
|
4
|
|
|
110
|
|
|||
Other comprehensive income (loss), net of taxes
|
125
|
|
|
(513
|
)
|
|
175
|
|
|||
Comprehensive loss
|
$
|
(6,771
|
)
|
|
$
|
(17,718
|
)
|
|
$
|
(21,002
|
)
|
Trupanion, Inc.
Consolidated Balance Sheets
(in thousands, except for share data)
|
|||||||
|
Years Ended December 31,
|
||||||
|
2016
|
|
2015
|
||||
Assets
|
|
|
|
||||
Current assets:
|
|
|
|
||||
Cash and cash equivalents
|
$
|
23,637
|
|
|
$
|
17,956
|
|
Short-term investments
|
29,570
|
|
|
25,288
|
|
||
Accounts and other receivables
|
10,118
|
|
|
8,196
|
|
||
Prepaid expenses and other assets
|
2,062
|
|
|
2,193
|
|
||
Total current assets
|
65,387
|
|
|
53,633
|
|
||
Restricted cash
|
600
|
|
|
—
|
|
||
Long-term investments, at fair value
|
2,579
|
|
|
2,388
|
|
||
Equity method investment
|
271
|
|
|
300
|
|
||
Property and equipment, net
|
8,464
|
|
|
9,719
|
|
||
Intangible assets, net
|
4,910
|
|
|
4,854
|
|
||
Other long term assets
|
134
|
|
|
23
|
|
||
Total assets
|
$
|
82,345
|
|
|
$
|
70,917
|
|
Liabilities and stockholders’ equity
|
|
|
|
||||
Current liabilities:
|
|
|
|
||||
Accounts payable
|
$
|
2,006
|
|
|
$
|
1,289
|
|
Accrued liabilities
|
4,322
|
|
|
4,189
|
|
||
Claims reserve
|
9,521
|
|
|
6,274
|
|
||
Deferred revenue
|
13,463
|
|
|
11,042
|
|
||
Deferred tax liabilities
|
251
|
|
|
169
|
|
||
Other payables
|
1,094
|
|
|
654
|
|
||
Total current liabilities
|
30,657
|
|
|
23,617
|
|
||
Long-term debt
|
4,767
|
|
|
—
|
|
||
Deferred tax liabilities
|
1,372
|
|
|
1,433
|
|
||
Other liabilities
|
834
|
|
|
511
|
|
||
Total liabilities
|
37,630
|
|
|
25,561
|
|
||
Stockholders’ equity:
|
|
|
|
||||
Common stock, $0.00001 par value per share, 100,000,000 shares authorized at December 31, 2016 and 200,000,000 shares authorized at December 31, 2015, 30,156,247 and 29,498,947 shares issued and outstanding at December 31, 2016; 29,017,168 and 28,396,189 shares issued and outstanding at December 31, 2015.
|
—
|
|
|
—
|
|
||
Preferred stock: $0.00001 par value per share, 10,000,000 shares authorized at December 31, 2016 and December 31, 2015, and 0 shares issued and outstanding at December 31, 2016 and December 31, 2015.
|
—
|
|
|
—
|
|
||
Additional paid-in capital
|
129,574
|
|
|
122,844
|
|
||
Accumulated other comprehensive loss
|
(377
|
)
|
|
(502
|
)
|
||
Accumulated deficit
|
(81,281
|
)
|
|
(74,385
|
)
|
||
Treasury stock, at cost: 657,300 shares at December 31, 2016, and 620,979 shares at December 31, 2015.
|
(3,201
|
)
|
|
(2,601
|
)
|
||
Total stockholders’ equity
|
44,715
|
|
|
45,356
|
|
||
Total liabilities and stockholders’ equity
|
$
|
82,345
|
|
|
$
|
70,917
|
|
Trupanion, Inc.
Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders
’
Equity (Deficit)
(in thousands, except share amounts)
|
||||||||||||||||||||||||||||||
|
Redeemable Convertible Preferred Stock
|
Common Stock
|
Special Voting Shares
|
Additional Paid-in Capital
|
Accumulated Deficit
|
Accumulated Other Comprehensive Income (Loss)
|
Treasury Stock
|
Total Stockholders' (Deficit) Equity
|
||||||||||||||||||||||
|
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
||||||||||||||||||||||||
Balance at December 31, 2013
|
14,857,989
|
|
31,724
|
|
2,236,641
|
|
—
|
|
2,247,130
|
|
—
|
|
5,769
|
|
(36,003
|
)
|
(164
|
)
|
(2,601
|
)
|
(32,999
|
)
|
||||||||
Conversion of special voting shares to common stock
|
—
|
|
—
|
|
2,247,130
|
|
—
|
|
(2,247,130
|
)
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
||||||||
Conversion of preferred stock to common stock
|
(14,944,945
|
)
|
(32,724
|
)
|
14,944,945
|
|
—
|
|
—
|
|
—
|
|
32,724
|
|
—
|
|
—
|
|
—
|
|
32,724
|
|
||||||||
Exercise of warrants
|
86,956
|
|
1,000
|
|
25,170
|
|
—
|
|
—
|
|
—
|
|
270
|
|
—
|
|
—
|
|
—
|
|
270
|
|
||||||||
Proceeds from IPO, net of issuance costs
|
—
|
|
—
|
|
8,193,750
|
|
—
|
|
—
|
|
—
|
|
72,722
|
|
—
|
|
—
|
|
—
|
|
72,722
|
|
||||||||
Reclassification of warrant liabilities
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
3,180
|
|
—
|
|
—
|
|
—
|
|
3,180
|
|
||||||||
Issuance of common stock upon exercise of stock options and vesting of restricted stock units
|
—
|
|
—
|
|
183,305
|
|
—
|
|
—
|
|
—
|
|
181
|
|
—
|
|
—
|
|
—
|
|
181
|
|
||||||||
Stock-based compensation expense
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
4,199
|
|
—
|
|
—
|
|
—
|
|
4,199
|
|
||||||||
Other comprehensive income (loss)
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
175
|
|
—
|
|
175
|
|
||||||||
Net loss
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
(21,177
|
)
|
—
|
|
—
|
|
(21,177
|
)
|
||||||||
Balance at December 31, 2014
|
—
|
|
—
|
|
27,830,941
|
|
—
|
|
—
|
|
—
|
|
119,045
|
|
(57,180
|
)
|
11
|
|
(2,601
|
)
|
59,275
|
|
||||||||
Issuance of restricted stock
|
—
|
|
—
|
|
4,616
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
||||||||
Tax withholding on restricted stock
|
—
|
|
—
|
|
(72,197
|
)
|
—
|
|
—
|
|
—
|
|
(643
|
)
|
—
|
|
—
|
|
—
|
|
(643
|
)
|
||||||||
Exercise of stock options
|
—
|
|
—
|
|
632,829
|
|
—
|
|
—
|
|
—
|
|
1,335
|
|
—
|
|
—
|
|
—
|
|
1,335
|
|
||||||||
Stock-based compensation expense
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
3,107
|
|
—
|
|
—
|
|
—
|
|
3,107
|
|
||||||||
Other comprehensive income (loss)
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
(513
|
)
|
—
|
|
(513
|
)
|
||||||||
Net loss
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
(17,205
|
)
|
—
|
|
—
|
|
(17,205
|
)
|
||||||||
Balance at December 31, 2015
|
—
|
|
—
|
|
28,396,189
|
|
—
|
|
—
|
|
—
|
|
122,844
|
|
(74,385
|
)
|
(502
|
)
|
(2,601
|
)
|
45,356
|
|
||||||||
Issuance of restricted stock
|
—
|
|
—
|
|
2,511
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
||||||||
Tax withholding on restricted stock
|
—
|
|
—
|
|
(42,798
|
)
|
—
|
|
—
|
|
—
|
|
(662
|
)
|
—
|
|
—
|
|
—
|
|
(662
|
)
|
||||||||
Exercise of stock options
|
—
|
|
—
|
|
1,119,367
|
|
—
|
|
—
|
|
—
|
|
3,745
|
|
—
|
|
—
|
|
—
|
|
3,745
|
|
||||||||
Exercise of warrants
|
—
|
|
—
|
|
59,999
|
|
—
|
|
—
|
|
—
|
|
600
|
|
—
|
|
—
|
|
—
|
|
600
|
|
||||||||
Purchase of treasury stock
|
—
|
|
—
|
|
(36,321
|
)
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
(600
|
)
|
(600
|
)
|
||||||||
Stock-based compensation expense
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
3,047
|
|
—
|
|
—
|
|
—
|
|
3,047
|
|
||||||||
Other comprehensive income (loss)
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
125
|
|
—
|
|
125
|
|
||||||||
Net loss
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
(6,896
|
)
|
—
|
|
—
|
|
(6,896
|
)
|
||||||||
Balance at December 31, 2016
|
—
|
|
$
|
—
|
|
29,498,947
|
|
$
|
—
|
|
—
|
|
$
|
—
|
|
$
|
129,574
|
|
$
|
(81,281
|
)
|
$
|
(377
|
)
|
$
|
(3,201
|
)
|
$
|
44,715
|
|
Trupanion, Inc.
Consolidated Statements of Cash Flows
(in thousands)
|
|||||||||||
|
Years Ended December 31,
|
||||||||||
|
|||||||||||
|
2016
|
|
2015
|
|
2014
|
||||||
Operating activities
|
|
|
|
|
|
||||||
Net loss
|
$
|
(6,896
|
)
|
|
$
|
(17,205
|
)
|
|
$
|
(21,177
|
)
|
Adjustments to reconcile net loss to cash used in operating activities:
|
|
|
|
|
|
||||||
Depreciation and amortization
|
3,846
|
|
|
2,542
|
|
|
1,674
|
|
|||
Amortization of debt discount and prepaid loan fees
|
58
|
|
|
21
|
|
|
5,033
|
|
|||
Warrant income
|
—
|
|
|
—
|
|
|
(1,574
|
)
|
|||
Stock-based compensation expense
|
2,946
|
|
|
3,002
|
|
|
4,084
|
|
|||
Other, net
|
46
|
|
|
(89
|
)
|
|
57
|
|
|||
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|||||
Accounts and other receivable
|
(1,830
|
)
|
|
(328
|
)
|
|
(126
|
)
|
|||
Prepaid expenses and other current assets
|
48
|
|
|
(905
|
)
|
|
(369
|
)
|
|||
Accounts payable
|
652
|
|
|
(347
|
)
|
|
449
|
|
|||
Accrued liabilities
|
175
|
|
|
51
|
|
|
551
|
|
|||
Claims reserve
|
3,226
|
|
|
1,241
|
|
|
(505
|
)
|
|||
Deferred revenue
|
2,398
|
|
|
1,779
|
|
|
877
|
|
|||
Other payables
|
337
|
|
|
(187
|
)
|
|
225
|
|
|||
Net cash provided by (used in) operating activities
|
5,006
|
|
|
(10,425
|
)
|
|
(10,801
|
)
|
|||
Investing activities
|
|
|
|
|
|
||||||
Purchases of investment securities
|
(31,616
|
)
|
|
(24,800
|
)
|
|
(34,894
|
)
|
|||
Maturities of investment securities
|
27,247
|
|
|
20,180
|
|
|
28,601
|
|
|||
Equity method investment
|
—
|
|
|
(300
|
)
|
|
—
|
|
|||
Purchases of property and equipment
|
(1,941
|
)
|
|
(4,894
|
)
|
|
(5,633
|
)
|
|||
Other
|
(198
|
)
|
|
(109
|
)
|
|
—
|
|
|||
Net cash used in investing activities
|
(6,508
|
)
|
|
(9,923
|
)
|
|
(11,926
|
)
|
|||
Financing activities
|
|
|
|
|
|
|
|||||
Tax withholding on restricted stock
|
(662
|
)
|
|
(643
|
)
|
|
—
|
|
|||
Proceeds from exercise of stock options
|
3,745
|
|
|
1,335
|
|
|
211
|
|
|||
Proceeds from (repayment of) debt financing
|
4,988
|
|
|
(14,900
|
)
|
|
(15,000
|
)
|
|||
Payments on capital lease obligations
|
(204
|
)
|
|
—
|
|
|
—
|
|
|||
Other financing costs
|
(195
|
)
|
|
—
|
|
|
(103
|
)
|
|||
Net proceeds from IPO
|
—
|
|
|
—
|
|
|
72,755
|
|
|||
Net cash provided by (used in) financing activities
|
7,672
|
|
|
(14,208
|
)
|
|
57,863
|
|
|||
Effect of foreign exchange rates on cash, net
|
111
|
|
|
(586
|
)
|
|
23
|
|
|||
Net change in cash, cash equivalents, and restricted cash
|
6,281
|
|
|
(35,142
|
)
|
|
35,159
|
|
|||
Cash, cash equivalents, and restricted cash at beginning of period
|
17,956
|
|
|
53,098
|
|
|
17,939
|
|
|||
Cash, cash equivalents, and restricted cash at end of period
|
$
|
24,237
|
|
|
$
|
17,956
|
|
|
$
|
53,098
|
|
Supplemental disclosures
|
|
|
|
|
|
|
|||||
Income taxes paid
|
19
|
|
|
139
|
|
|
9
|
|
|||
Interest paid
|
153
|
|
|
155
|
|
|
1,494
|
|
|||
Noncash investing and financing activities:
|
|
|
|
|
|
||||||
Warrants issued in conjunction with debt issuance
|
—
|
|
|
—
|
|
|
1,124
|
|
|||
Increase in payables for property and equipment
|
104
|
|
|
98
|
|
|
911
|
|
|||
Cashless exercise of preferred stock warrants
|
—
|
|
|
—
|
|
|
1,270
|
|
|||
Cashless exercise of common stock warrants
|
600
|
|
|
—
|
|
|
—
|
|
|||
Common stock warrant reclassification to equity
|
—
|
|
|
—
|
|
|
3,180
|
|
|||
Property and equipment acquired under capital lease
|
559
|
|
|
—
|
|
|
—
|
|
|
|
Years Ended December 31,
|
||||||||||
|
|
2016
|
|
2015
|
|
2014
|
||||||
Deferred acquisition costs capitalized
|
|
$
|
12,251
|
|
|
$
|
10,184
|
|
|
$
|
7,995
|
|
Deferred acquisition costs amortized:
|
|
|
|
|
|
|
||||||
Sales and marketing
|
|
1,401
|
|
|
1,490
|
|
|
858
|
|
|||
Other cost of revenue
|
|
10,743
|
|
|
8,606
|
|
|
7,052
|
|
|||
Total amortization
|
|
12,144
|
|
|
10,096
|
|
|
7,910
|
|
|||
Balance at December 31,
|
|
$
|
664
|
|
|
$
|
557
|
|
|
$
|
469
|
|
|
|
Years Ended December 31,
|
||||||||||
|
|
2016
|
|
2015
|
|
2014
|
||||||
Interest income
|
|
$
|
(119
|
)
|
|
$
|
(75
|
)
|
|
$
|
(73
|
)
|
Foreign exchange loss
|
|
—
|
|
|
36
|
|
|
41
|
|
|||
Loss on disposal of fixed assets
|
|
24
|
|
|
20
|
|
|
111
|
|
|||
Warrant remeasurement
|
|
—
|
|
|
—
|
|
|
(1,574
|
)
|
|||
Other
|
|
37
|
|
|
10
|
|
|
8
|
|
|||
Other income, net
|
|
$
|
(58
|
)
|
|
$
|
(9
|
)
|
|
$
|
(1,487
|
)
|
|
As of December 31,
|
|||||||
|
2016
|
|
2015
|
|
2014
|
|||
Stock options
|
4,123,023
|
|
|
4,871,949
|
|
|
5,112,556
|
|
Restricted stock awards and units
|
352,996
|
|
|
472,384
|
|
|
592,625
|
|
Warrants
|
810,000
|
|
|
869,999
|
|
|
869,999
|
|
|
Years Ended December 31,
|
||||||
|
2016
|
|
2015
|
||||
Office and telephone equipment (5 years)
|
$
|
129
|
|
|
$
|
127
|
|
PC and networking hardware (3–4 years)
|
1,191
|
|
|
1,177
|
|
||
Software (3–5 years)
|
14,340
|
|
|
12,547
|
|
||
Furniture and fixtures (5 years)
|
618
|
|
|
711
|
|
||
Vehicles (5 years)
|
54
|
|
|
54
|
|
||
Fixed assets under capital lease (over less of expected useful life or life of lease)
|
478
|
|
|
—
|
|
||
Leasehold improvement (over less of expected useful life or life of lease)
|
—
|
|
|
621
|
|
||
Property and equipment
|
16,810
|
|
|
15,237
|
|
||
Accumulated depreciation
|
(8,346
|
)
|
|
(5,518
|
)
|
||
Property and equipment, net
|
$
|
8,464
|
|
|
$
|
9,719
|
|
|
Amortized
Cost |
|
Gross
Unrealized Holding Losses |
|
Fair
Value |
||||||
As of December 31, 2016
|
|
|
|
|
|
||||||
Available-for-sale:
|
|
|
|
|
|
||||||
Foreign deposits
|
$
|
1,587
|
|
|
$
|
—
|
|
|
$
|
1,587
|
|
Municipal bond
|
1,000
|
|
|
(8
|
)
|
|
$
|
992
|
|
||
|
$
|
2,587
|
|
|
$
|
(8
|
)
|
|
$
|
2,579
|
|
Short-term investments:
|
|
|
|
|
|
||||||
U.S. Treasury securities
|
$
|
5,791
|
|
|
$
|
—
|
|
|
$
|
5,791
|
|
Certificates of deposit
|
707
|
|
|
—
|
|
|
707
|
|
|||
U.S. government funds
|
23,072
|
|
|
—
|
|
|
23,072
|
|
|||
|
$
|
29,570
|
|
|
$
|
—
|
|
|
$
|
29,570
|
|
|
|
|
|
|
|
||||||
|
Amortized
Cost |
|
Gross
Unrealized Holding Losses |
|
Fair
Value |
||||||
As of December 31, 2015
|
|
|
|
|
|
||||||
Available-for-sale:
|
|
|
|
|
|
||||||
Foreign deposits
|
$
|
1,442
|
|
|
$
|
—
|
|
|
$
|
1,442
|
|
Municipal bond
|
1,000
|
|
|
(54
|
)
|
|
946
|
|
|||
|
$
|
2,442
|
|
|
$
|
(54
|
)
|
|
$
|
2,388
|
|
Short-term investments:
|
|
|
|
|
|
||||||
U.S. Treasury securities
|
$
|
5,683
|
|
|
$
|
—
|
|
|
$
|
5,683
|
|
Certificates of deposit
|
1,551
|
|
|
—
|
|
|
$
|
1,551
|
|
||
U.S. government funds
|
18,054
|
|
|
—
|
|
|
$
|
18,054
|
|
||
|
$
|
25,288
|
|
|
$
|
—
|
|
|
$
|
25,288
|
|
|
December 31, 2016
|
||||||
|
Amortized
Cost |
|
Fair
Value |
||||
Available-for-sale:
|
|
|
|
||||
Due under one year
|
$
|
—
|
|
|
$
|
—
|
|
Due after one year through five years
|
1,587
|
|
|
1,587
|
|
||
Due after five years through ten years
|
1,000
|
|
|
992
|
|
||
Due after ten years
|
—
|
|
|
—
|
|
||
|
$
|
2,587
|
|
|
$
|
2,579
|
|
•
|
Level 1 inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.
|
•
|
Level 2 inputs: Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.
|
•
|
Level 3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.
|
|
As of December 31, 2016
|
||||||||||||||
|
Fair Value
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
||||||||
Assets
|
|
|
|
|
|
|
|
||||||||
Restricted cash
|
$
|
600
|
|
|
$
|
600
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Foreign deposits
|
1,587
|
|
|
1,587
|
|
|
—
|
|
|
—
|
|
||||
Municipal bond
|
992
|
|
|
—
|
|
|
992
|
|
|
—
|
|
||||
Money market funds
|
7,033
|
|
|
7,033
|
|
|
—
|
|
|
—
|
|
||||
Total
|
$
|
10,212
|
|
|
$
|
9,220
|
|
|
$
|
992
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
||||||||
|
As of December 31, 2015
|
||||||||||||||
|
Fair Value
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
||||||||
Assets
|
|
|
|
|
|
|
|
||||||||
Foreign deposits
|
$
|
1,442
|
|
|
$
|
1,442
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Municipal bond
|
946
|
|
|
—
|
|
|
946
|
|
|
—
|
|
||||
Money market funds
|
7,545
|
|
|
7,545
|
|
|
—
|
|
|
—
|
|
||||
Total
|
$
|
9,933
|
|
|
$
|
8,987
|
|
|
$
|
946
|
|
|
$
|
—
|
|
Year ending December 31:
|
|
||
2017
|
$
|
1,510
|
|
2018
|
1,860
|
|
|
2019
|
2,020
|
|
|
2020
|
2,101
|
|
|
2021
|
2,182
|
|
|
Thereafter
|
11,029
|
|
|
Total minimum lease payments
|
$
|
20,702
|
|
Year ending December 31:
|
|
||
2017
|
$
|
3,624
|
|
2018
|
1,681
|
|
|
2019
|
764
|
|
|
2020
|
119
|
|
|
2021
|
17
|
|
|
Thereafter
|
—
|
|
|
Total minimum commitment
|
$
|
6,205
|
|
|
|
Years Ended December 31,
|
||||||||||
|
|
2016
|
|
2015
|
|
2014
|
||||||
Claims reserve at beginning of year - subscription business
|
|
$
|
5,384
|
|
|
$
|
4,278
|
|
|
$
|
4,573
|
|
Claims incurred during the year related to:
|
|
|
|
|
|
|
||||||
Current year - subscription business
|
|
123,823
|
|
|
95,390
|
|
|
74,471
|
|
|||
Prior years - subscription business
|
|
813
|
|
|
30
|
|
|
(132
|
)
|
|||
Total claims incurred
|
|
124,636
|
|
|
95,420
|
|
|
74,339
|
|
|||
Claims paid during year related to:
|
|
|
|
|
|
|
||||||
Current year - subscription business
|
|
115,314
|
|
|
89,768
|
|
|
69,956
|
|
|||
Prior years - subscription business
|
|
5,832
|
|
|
4,239
|
|
|
4,442
|
|
|||
Total claims paid
|
|
121,146
|
|
|
94,007
|
|
|
74,398
|
|
|||
Non-cash claims expense - subscription business
|
|
336
|
|
|
307
|
|
|
236
|
|
|||
Claims reserve at end of year - subscription business
|
|
$
|
8,538
|
|
|
$
|
5,384
|
|
|
$
|
4,278
|
|
|
|
Years Ended December 31,
|
||||||||||
|
|
2016
|
|
2015
|
|
2014
|
||||||
Claims reserve at beginning of year - other business
|
|
$
|
890
|
|
|
$
|
829
|
|
|
$
|
1,039
|
|
Claims incurred during the year related to:
|
|
|
|
|
|
|
||||||
Current year - other business
|
|
9,027
|
|
|
7,983
|
|
|
5,967
|
|
|||
Prior years - other business
|
|
(129
|
)
|
|
(79
|
)
|
|
(393
|
)
|
|||
Total claims incurred
|
|
8,898
|
|
|
7,904
|
|
|
5,574
|
|
|||
Claims paid during year related to:
|
|
|
|
|
|
|
||||||
Current year - other business
|
|
8,048
|
|
|
7,095
|
|
|
5,138
|
|
|||
Prior years - other business
|
|
757
|
|
|
748
|
|
|
646
|
|
|||
Total claims paid
|
|
8,805
|
|
|
7,843
|
|
|
5,784
|
|
|||
Non-cash claims expense - other business
|
|
—
|
|
|
—
|
|
|
—
|
|
|||
Claims reserve at end of year - other business
|
|
$
|
983
|
|
|
$
|
890
|
|
|
$
|
829
|
|
|
|
Years Ended December 31,
|
|
As of December 31, 2016
|
|||||||||||||||||||
|
|
Incurred claims and claim adjustment expenses
|
|
Total of IBNR plus expected development on reported claims
|
|
Cumulative number of reported claims
|
|||||||||||||||||
Year Incurred
|
|
2013
|
|
2014
|
|
2015
|
|
2016
|
|
|
|||||||||||||
|
|
(unaudited)
|
|
(unaudited)
|
|
(unaudited)
|
|
|
|
|
|
|
|||||||||||
2013
|
|
$
|
49,595
|
|
|
$
|
49,475
|
|
|
$
|
49,593
|
|
|
$
|
49,629
|
|
|
$
|
8
|
|
|
269,849
|
|
2014
|
|
|
|
$
|
71,008
|
|
|
$
|
70,954
|
|
|
$
|
71,118
|
|
|
$
|
71
|
|
|
377,083
|
|
||
2015
|
|
|
|
|
|
$
|
94,354
|
|
|
$
|
94,908
|
|
|
$
|
286
|
|
|
469,815
|
|
||||
2016
|
|
|
|
|
|
|
|
$
|
123,478
|
|
|
$
|
8,173
|
|
|
538,427
|
|
||||||
|
|
$
|
339,133
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
As of December 31, 2016
|
|||||||||||||||||||
|
|
Incurred claims and claim adjustment expenses
|
|
Total of IBNR plus expected development on reported claims
|
|
Cumulative number of reported claims
|
|||||||||||||||||
Year Incurred
|
|
2013
|
|
2014
|
|
2015
|
|
2016
|
|
|
|||||||||||||
|
|
(unaudited)
|
|
(unaudited)
|
|
(unaudited)
|
|
|
|
|
|
|
|||||||||||
2013
|
|
$
|
3,294
|
|
|
$
|
2,841
|
|
|
$
|
2,849
|
|
|
$
|
2,849
|
|
|
$
|
—
|
|
|
18,169
|
|
2014
|
|
|
|
$
|
5,966
|
|
|
$
|
5,888
|
|
|
$
|
5,887
|
|
|
$
|
1
|
|
|
34,535
|
|
||
2015
|
|
|
|
|
|
$
|
7,973
|
|
|
$
|
7,845
|
|
|
$
|
3
|
|
|
46,713
|
|
||||
2016
|
|
|
|
|
|
|
|
$
|
9,027
|
|
|
$
|
979
|
|
|
53,723
|
|
||||||
|
|
$
|
25,608
|
|
|
|
|
|
|
|
Years Ended
December 31,
|
||||
|
|
2016
|
|
2015
|
|
2014
|
Valuation assumptions:
|
|
|
|
|
|
|
Expected term (in years)
|
|
5.04-6.25
|
|
3.0-6.25
|
|
6.25
|
Expected volatility
|
|
37.6%-42.1%
|
|
37.2%–49.4%
|
|
54.3%–59.3%
|
Risk-free interest rate
|
|
1.1%-2.0%
|
|
1.1%–2.0%
|
|
1.8%–2.0%
|
Expected dividend yield
|
|
—%
|
|
—%
|
|
—%
|
|
Number
of
Options
|
|
Weighted-
Average
Exercise
Price
|
|
Aggregate
Intrinsic
Value
(in thousands)
|
|||||
December 31, 2013
|
4,663,445
|
|
|
2.12
|
|
|
30,406
|
|
||
Granted
|
754,200
|
|
|
9.64
|
|
|
—
|
|
||
Exercised
|
(176,595
|
)
|
|
1.20
|
|
|
1,428
|
|
||
Forfeited
|
(128,494
|
)
|
|
5.40
|
|
|
—
|
|
||
December 31, 2014
|
5,112,556
|
|
|
3.19
|
|
|
21,116
|
|
||
Granted
|
698,764
|
|
|
7.84
|
|
|
—
|
|
||
Exercised
|
(632,829
|
)
|
|
2.12
|
|
|
3,703
|
|
||
Forfeited
|
(306,542
|
)
|
|
7.65
|
|
|
—
|
|
||
December 31, 2015
|
4,871,949
|
|
|
3.71
|
|
|
29,644
|
|
||
Granted
|
666,664
|
|
|
13.37
|
|
|
—
|
|
||
Exercised
|
(1,119,367
|
)
|
|
3.35
|
|
|
11,980
|
|
||
Forfeited
|
(296,223
|
)
|
|
8.14
|
|
|
—
|
|
||
December 31, 2016
|
4,123,023
|
|
|
5.06
|
|
|
43,185
|
|
||
|
|
|
|
|
|
|||||
Vested and exercisable at December 31, 2016
|
3,119,438
|
|
|
$
|
3.06
|
|
|
$
|
38,856
|
|
|
|
Weighted- Average Grant Date Fair Value
|
|
Fair Value
of Options
Vested
|
||||
|
|
(per share)
|
|
(in thousands)
|
||||
Year:
|
|
|
|
|
||||
2014
|
|
$
|
5.33
|
|
|
$
|
2,203
|
|
2015
|
|
$
|
3.46
|
|
|
$
|
3,796
|
|
2016
|
|
$
|
5.64
|
|
|
$
|
6,688
|
|
|
|
Number of
Shares
|
|
Weighted- Average
Grant Date Fair Value Per
Restricted Stock
|
|||
Nonvested stock award balance at December 31, 2013
|
|
722,226
|
|
|
$
|
4.77
|
|
Restricted stock awards granted
|
|
6,126
|
|
|
5.79
|
|
|
Awards upon which restrictions lapsed
|
|
(143,967
|
)
|
|
4.81
|
|
|
Restricted stock awards forfeited
|
|
—
|
|
|
—
|
|
|
Nonvested stock award balance at December 31, 2014
|
|
584,385
|
|
|
4.77
|
|
|
Restricted stock awards granted
|
|
2,385
|
|
|
7.26
|
|
|
Awards upon which restrictions lapsed
|
|
(119,262
|
)
|
|
4.80
|
|
|
Restricted stock awards forfeited
|
|
—
|
|
|
—
|
|
|
Nonvested stock award balance at December 31, 2015
|
|
467,508
|
|
|
4.77
|
|
|
Restricted stock awards granted
|
|
—
|
|
|
—
|
|
|
Awards upon which restrictions lapsed
|
|
(116,877
|
)
|
|
4.77
|
|
|
Restricted stock awards forfeited
|
|
—
|
|
|
—
|
|
|
Nonvested stock award balance at December 31, 2016
|
|
350,631
|
|
|
4.77
|
|
|
Years Ended December 31,
|
||||||||||
|
2016
|
|
2015
|
|
2014
|
||||||
Claims expenses
|
$
|
234
|
|
|
$
|
219
|
|
|
$
|
236
|
|
Other cost of revenue
|
41
|
|
|
44
|
|
|
79
|
|
|||
Sales and marketing
|
532
|
|
|
446
|
|
|
553
|
|
|||
Technology and development
|
246
|
|
|
404
|
|
|
461
|
|
|||
General and administrative
|
1,893
|
|
|
1,889
|
|
|
2,755
|
|
|||
Total stock-based compensation
|
$
|
2,946
|
|
|
$
|
3,002
|
|
|
$
|
4,084
|
|
|
Years Ended December 31,
|
||||||||||
|
2016
|
|
2015
|
|
2014
|
||||||
Revenue:
|
|
|
|
|
|
||||||
Subscription business
|
$
|
173,356
|
|
|
$
|
133,406
|
|
|
$
|
103,502
|
|
Other business
|
14,874
|
|
|
13,557
|
|
|
12,408
|
|
|||
|
188,230
|
|
|
146,963
|
|
|
115,910
|
|
|||
Claims expenses:
|
|
|
|
|
|
||||||
Subscription business
|
124,636
|
|
|
95,420
|
|
|
74,206
|
|
|||
Other business
|
8,898
|
|
|
7,904
|
|
|
5,707
|
|
|||
|
133,534
|
|
|
103,324
|
|
|
79,913
|
|
|||
Other cost of revenue:
|
|
|
|
|
|
||||||
Subscription business
|
16,685
|
|
|
14,008
|
|
|
10,963
|
|
|||
Other business
|
4,723
|
|
|
4,402
|
|
|
5,160
|
|
|||
|
21,408
|
|
|
18,410
|
|
|
16,123
|
|
|||
Gross profit:
|
|
|
|
|
|
||||||
Subscription business
|
32,035
|
|
|
23,978
|
|
|
18,333
|
|
|||
Other business
|
1,253
|
|
|
1,251
|
|
|
1,541
|
|
|||
|
33,288
|
|
|
25,229
|
|
|
19,874
|
|
|||
Sales and marketing:
|
|
|
|
|
|
||||||
Subscription business
|
15,029
|
|
|
15,151
|
|
|
11,484
|
|
|||
Other business
|
218
|
|
|
80
|
|
|
124
|
|
|||
|
15,247
|
|
|
15,231
|
|
|
11,608
|
|
|||
Technology and development
|
9,534
|
|
|
11,215
|
|
|
9,899
|
|
|||
General and administrative
|
15,205
|
|
|
15,558
|
|
|
14,312
|
|
|||
Operating loss
|
$
|
(6,698
|
)
|
|
$
|
(16,775
|
)
|
|
$
|
(15,945
|
)
|
|
|
As of December 31,
|
||||||||||
|
|
2016
|
|
2015
|
|
2014
|
||||||
Statutory net income
|
|
$
|
4,081
|
|
|
$
|
1,386
|
|
|
$
|
990
|
|
Statutory capital and surplus
|
|
30,451
|
|
|
26,068
|
|
|
23,661
|
|
|
|
Years Ended December 31,
|
||||||||||
|
|
2016
|
|
2015
|
|
2014
|
||||||
Current:
|
|
|
|
|
|
|
||||||
U.S. federal & state
|
|
$
|
25
|
|
|
$
|
31
|
|
|
$
|
26
|
|
Foreign
|
|
13
|
|
|
84
|
|
|
(30
|
)
|
|||
|
|
38
|
|
|
115
|
|
|
(4
|
)
|
|||
Deferred:
|
|
|
|
|
|
|
||||||
U.S. federal & state
|
|
—
|
|
|
—
|
|
|
—
|
|
|||
Foreign
|
|
—
|
|
|
(1
|
)
|
|
(3
|
)
|
|||
|
|
—
|
|
|
(1
|
)
|
|
(3
|
)
|
|||
Income tax expense (benefit)
|
|
$
|
38
|
|
|
$
|
114
|
|
|
$
|
(7
|
)
|
|
|
Years Ended December 31,
|
||||||
|
|
2016
|
|
2015
|
||||
Deferred tax assets:
|
|
|
|
|
||||
Current:
|
|
|
|
|
||||
Unearned premium reserves
|
|
$
|
918
|
|
|
$
|
745
|
|
Loss reserves
|
|
27
|
|
|
167
|
|
||
Other
|
|
782
|
|
|
690
|
|
||
Noncurrent:
|
|
|
|
|
||||
Net operating loss carryforwards
|
|
22,632
|
|
|
20,514
|
|
||
Depreciation and amortization
|
|
535
|
|
|
451
|
|
||
Equity compensation
|
|
1,137
|
|
|
713
|
|
||
Other
|
|
156
|
|
|
96
|
|
||
Total deferred tax assets
|
|
26,187
|
|
|
23,376
|
|
||
Deferred tax liabilities:
|
|
|
|
|
||||
Current:
|
|
|
|
|
||||
Deferred costs
|
|
(226
|
)
|
|
(189
|
)
|
||
Noncurrent:
|
|
|
|
|
||||
Intangible assets
|
|
(1,623
|
)
|
|
(1,623
|
)
|
||
Other
|
|
(77
|
)
|
|
(72
|
)
|
||
Total deferred tax liabilities
|
|
(1,926
|
)
|
|
(1,884
|
)
|
||
Total deferred taxes
|
|
24,261
|
|
|
21,492
|
|
||
Less deferred tax asset valuation allowance
|
|
(25,879
|
)
|
|
(23,110
|
)
|
||
Net deferred taxes
|
|
$
|
(1,618
|
)
|
|
$
|
(1,618
|
)
|
|
|
Years Ended
December 31,
|
||||||||||
|
|
2016
|
|
2015
|
|
2014
|
||||||
Balance, beginning of year
|
|
$
|
80
|
|
|
$
|
65
|
|
|
$
|
390
|
|
Decreases to tax positions related to prior periods
|
|
—
|
|
|
—
|
|
|
(346
|
)
|
|||
Increases to tax positions related to the current year
|
|
40
|
|
|
15
|
|
|
21
|
|
|||
Balance, end of year
|
|
$
|
120
|
|
|
$
|
80
|
|
|
$
|
65
|
|
|
|
TRUPANION, INC.
|
|
|
|
By:
|
|
/s/ Darryl Rawlings
|
|
|
Darryl Rawlings
Chief Executive Officer and President
|
|
|
|
|
|
|
|
|
|
Date: February 15, 2017
|
|
/s/ Darryl Rawlings
|
|
|
Darryl Rawlings
Chief Executive Officer and President
(Principal Executive Officer)
|
|
|
|
Date: February 15, 2017
|
|
/s/ Tricia Plouf
|
|
|
Tricia Plouf
Chief Financial Officer (Principal Financial and Accounting Officer) |
|
|
|
Date: February 15, 2017
|
|
/s/ Murray Low
|
|
|
Murray Low
Chairman of the Board of Directors |
|
|
|
Date: February 15, 2017
|
|
/s/ Chad Cohen
|
|
|
Chad Cohen
Director |
|
|
|
Date: February 15, 2017
|
|
/s/ Michael Doak
|
|
|
Michael Doak
Director |
|
|
|
Date: February 15, 2017
|
|
/s/ Robin Ferracone
|
|
|
Robin Ferracone
Director |
|
|
|
Date: February 15, 2017
|
|
/s/ Dan Levitan
|
|
|
Dan Levitan
Director |
|
|
|
Date: February 15, 2017
|
|
/s/ H. Hays Lindsley
|
|
|
H. Hays Lindsley
Director |
|
|
|
Date: February 15, 2017
|
|
/s/ Glenn Novotny
|
|
|
Glenn Novotny
Director |
|
|
|
Date: February 15, 2017
|
|
/s/ Howard Rubin
|
|
|
Howard Rubin
Director |
Exhibit
|
|
|
|
Incorporated by Reference
|
|
Filed/Furnished
|
||||||
Number
|
|
Exhibit Description
|
|
Form
|
|
File No.
|
|
Exhibit
|
|
Exhibit Filing Date
|
|
Herewith
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.1
|
|
Restated Certificate of Incorporation of the Registrant.
|
|
10-Q
|
|
001-36537
|
|
3.1
|
|
8/28/2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.2
|
|
Certificate of Amendment to the Restated Certificated of Incorporation of Trupanion Inc.
|
|
8-K
|
|
001-36537
|
|
3.1
|
|
6/3/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.3
|
|
Restated Bylaws of the Registrant.
|
|
10-Q
|
|
001-36537
|
|
3.2
|
|
8/28/2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.1
|
|
Form of Common Stock Certificate.
|
|
S-1
|
|
333-196814
|
|
4.1
|
|
6/16/2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.2
|
|
Third Amended and Restated Registration Rights Agreement, dated October 25, 2011, by and among the Registrant and certain of its stockholders, as amended.
|
|
S-1
|
|
333-196814
|
|
4.4
|
|
6/16/2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.1+
|
|
Form of Indemnity Agreement.
|
|
S-1
|
|
333-196814
|
|
10.1
|
|
6/16/2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.2+
|
|
2007 Equity Compensation Plan and forms of stock option agreements and exercise notices, restricted stock notice agreement and restricted stock agreement thereunder.
|
|
S-1
|
|
333-196814
|
|
10.2
|
|
6/16/2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.3+
|
|
2014 Equity Incentive Plan and forms of stock option award agreement, restricted stock agreement and restricted stock unit award agreement thereunder.
|
|
S-1
|
|
333-196814
|
|
10.3
|
|
6/16/2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.4+
|
|
2014 Employee Stock Purchase Plan.
|
|
S-1
|
|
333-196814
|
|
10.4
|
|
6/16/2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.5+
|
|
Amended and Restated Employment Agreement, dated April 20, 2007, by and between the Registrant and Darryl Rawlings.
|
|
S-1
|
|
333-196814
|
|
10.6
|
|
6/16/2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.6+
|
|
Employment Agreement, dated June 13, 2012, by and between the Registrant and Michael Banks.
|
|
S-1
|
|
333-196814
|
|
10.7
|
|
6/16/2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.7+
|
|
Consulting Agreement, dated May 5, 2014, by and between the Registrant and Howard Rubin.
|
|
S-1
|
|
333-196814
|
|
10.8
|
|
6/16/2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.8+
|
|
Agency Agreement between Omega General Insurance Company and Trupanion Brokers Ontario, Inc., effective January 1, 2015.
|
|
10-K
|
|
001-36537
|
|
10.13
|
|
2/24/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.9+
|
|
Fronting and Administration Agreement between Wyndham Insurance Company (SAC) Limited and Omega General Insurance Company, effective January 1, 2015.
|
|
10-K
|
|
001-36537
|
|
10.14
|
|
2/24/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.10†
|
|
Quota Share Reinsurance Agreement between Wyndham Insurance Company (SAC) Limited and Omega General Insurance Company, effective January 1, 2015.
|
|
10-K
|
|
001-36537
|
|
10.15
|
|
2/24/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.11+
|
|
First Amendment to Consulting Agreement, dated January 1, 2016, by and between the Registrant and Howard Rubin.
|
|
10-Q
|
|
001-36537
|
|
10.2
|
|
5/5/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.12+
|
|
Amendment to Lease Agreement, dated December 7, 2015, by and between American Pet Insurance Company and Selig Real Estate Holdings XXXIV, LLC, as amended.
|
|
10-K
|
|
001-36537
|
|
10.16
|
|
2/16/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.13+
|
|
Second Amendment to Consulting Agreement, dated January 1, 2017 by and between the Registrant and Howard Rubin.
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.14+
|
|
Employment Agreement, dated January 13, 2017, by and between the Registrant and Tim Graff.
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.15+
|
|
Senior Credit Facility Loan and Security Agreement, entered into as of December 16, 2016 between Pacific Western Bank, Western Alliance Bank and Trupanion, Inc.
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.16+
|
|
Quota Share Reinsurance Agreement between Wyndham Insurance Company (SAC) Limited and Omega General Insurance Company, effective January 1, 2016.
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.17+
|
|
Quota Share Reinsurance Agreement between Wyndham Insurance Company (SAC) Limited and Omega General Insurance Company, effective January 1, 2017.
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21.1
|
|
Subsidiaries of the Registrant.
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.1
|
|
Consent of independent registered public accounting firm.
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24.1
|
|
Power of Attorney (reference is made to the signature page hereto)
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31.1
|
|
Certification of Principal Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31.2
|
|
Certification of Principal Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
32.1*
|
|
Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
32.2*
|
|
Certification of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.INS
|
|
XBRL Instance Document.
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.SCH
|
|
XBRL Taxonomy Extension Schema Document.
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase Document.
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase Document.
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase Document.
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase Document.
|
|
|
|
|
|
|
|
|
|
X
|
+
|
Indicates a management contract or compensatory plan or arrangement.
|
†
|
Registrant has omitted portions of the referenced exhibit pursuant to a request for confidential treatment under Rule 24b-2 promulgated under the Exchange Act. The omitted portions of this exhibit have been filed separately with the SEC.
|
*
|
This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.
|
Trupanion, Inc.
Condensed Statements of Comprehensive Loss
(Parent Company Only)
(In thousands)
|
||||||||||||
|
|
Years Ended December 31,
|
||||||||||
|
|
2016
|
|
2015
|
|
2014
|
||||||
Expenses:
|
|
|
||||||||||
Claims expenses
|
|
$
|
269
|
|
|
$
|
226
|
|
|
$
|
240
|
|
Other costs of revenue
|
|
41
|
|
|
44
|
|
|
79
|
|
|||
Sales and marketing
|
|
871
|
|
|
621
|
|
|
553
|
|
|||
Technology and development
|
|
531
|
|
|
628
|
|
|
528
|
|
|||
General and administrative
|
|
3,627
|
|
|
3,852
|
|
|
4,108
|
|
|||
Total expenses
|
|
5,339
|
|
|
5,371
|
|
|
5,508
|
|
|||
Operating loss
|
|
(5,339
|
)
|
|
(5,371
|
)
|
|
(5,508
|
)
|
|||
Interest expense
|
|
218
|
|
|
325
|
|
|
6,725
|
|
|||
Other expense (income)
|
|
23
|
|
|
(2
|
)
|
|
(1,575
|
)
|
|||
Loss before equity in undistributed earnings of subsidiaries
|
|
(5,580
|
)
|
|
(5,694
|
)
|
|
(10,658
|
)
|
|||
Equity in undistributed earnings of subsidiaries
|
|
(1,316
|
)
|
|
(11,511
|
)
|
|
(10,519
|
)
|
|||
Net loss
|
|
$
|
(6,896
|
)
|
|
$
|
(17,205
|
)
|
|
$
|
(21,177
|
)
|
Other comprehensive (loss) income, net of taxes:
|
|
|
|
|
|
|
||||||
Other comprehensive (loss) income of subsidiaries
|
|
125
|
|
|
(513
|
)
|
|
175
|
|
|||
Other comprehensive (loss) income
|
|
125
|
|
|
(513
|
)
|
|
175
|
|
|||
Comprehensive loss
|
|
$
|
(6,771
|
)
|
|
$
|
(17,718
|
)
|
|
$
|
(21,002
|
)
|
Trupanion, Inc.
Condensed Balance Sheets
(
Parent Company Only)
(In thousands, except for share and per share data)
|
||||||||
|
|
As of December 31,
|
||||||
|
|
2016
|
|
2015
|
||||
Assets
|
|
|
||||||
Current assets:
|
|
|
|
|
||||
Cash and cash equivalents
|
|
$
|
3,401
|
|
|
$
|
6,040
|
|
Accounts and other receivable
|
|
1,492
|
|
|
517
|
|
||
Prepaid expenses and other assets
|
|
106
|
|
|
364
|
|
||
Total current assets
|
|
4,999
|
|
|
6,921
|
|
||
Restricted cash
|
|
600
|
|
|
—
|
|
||
Equity method investment
|
|
271
|
|
|
300
|
|
||
Property and equipment, net
|
|
1,070
|
|
|
641
|
|
||
Intangible assets, net
|
|
4,773
|
|
|
4,784
|
|
||
Advances to and investments in subsidiaries
|
|
40,086
|
|
|
34,488
|
|
||
Total assets
|
|
$
|
51,799
|
|
|
$
|
47,134
|
|
Liabilities and stockholders’ equity
|
|
|
|
|
||||
Current liabilities:
|
|
|
|
|
||||
Accounts payable
|
|
$
|
19
|
|
|
$
|
11
|
|
Accrued liabilities
|
|
145
|
|
|
144
|
|
||
Deferred tax liabilities
|
|
250
|
|
|
169
|
|
||
Other liabilities
|
|
328
|
|
|
—
|
|
||
Total current liabilities
|
|
742
|
|
|
324
|
|
||
Long-term debt
|
|
4,767
|
|
|
—
|
|
||
Deferred tax liabilities
|
|
1,372
|
|
|
1,454
|
|
||
Other liabilities
|
|
203
|
|
|
—
|
|
||
Total liabilities
|
|
7,084
|
|
|
1,778
|
|
||
Stockholders’ equity:
|
|
|
|
|
||||
Common stock, $0.00001 par value per share, 100,000,000 shares authorized at December 31, 2016 and 200,000,000 shares authorized at December 31, 2015, 30,156,247 and 29,498,947 shares issued and outstanding at December 31, 2016; 29,017,168 and 28,396,189 shares issued and outstanding at December 31, 2015.
|
|
—
|
|
|
—
|
|
||
Preferred stock: $0.00001 par value per share, 10,000,000 shares authorized at December 31, 2016 and December 31, 2015, and 0 shares issued and outstanding at December 31, 2016 and December 31, 2015.
|
|
—
|
|
|
—
|
|
||
Additional paid-in capital
|
|
129,574
|
|
|
122,844
|
|
||
Accumulated other comprehensive (loss) income
|
|
(377
|
)
|
|
(502
|
)
|
||
Accumulated deficit
|
|
(81,281
|
)
|
|
(74,385
|
)
|
||
Treasury stock, at cost: 657,300 shares at December 31, 2016, and 620,979 shares at December 31, 2015.
|
|
(3,201
|
)
|
|
(2,601
|
)
|
||
Total stockholders’ equity
|
|
44,715
|
|
|
45,356
|
|
||
Total liabilities and stockholders’ equity
|
|
$
|
51,799
|
|
|
$
|
47,134
|
|
Trupanion, Inc.
Condensed Statements of Cash Flows
(Parent Company Only)
(In thousands)
|
|||||||||||
|
|
Years Ended December 31,
|
|||||||||
|
|
2016
|
|
2015
|
|
2014
|
|||||
Operating activities
|
|
|
|||||||||
Net loss
|
|
$
|
(6,896
|
)
|
|
$
|
(17,205
|
)
|
|
(21,177
|
)
|
Adjustments to reconcile net loss to cash (used in) provided by operating activities:
|
|
|
|
|
|
|
|||||
Loss attributable to equity method investments
|
|
1,316
|
|
|
11,511
|
|
|
10,519
|
|
||
Depreciation and amortization
|
|
251
|
|
|
126
|
|
|
67
|
|
||
Amortization of debt discount and prepaid loan fees
|
|
58
|
|
|
21
|
|
|
5,033
|
|
||
Warrant expense
|
|
—
|
|
|
—
|
|
|
(1,574
|
)
|
||
Stock-based compensation expense
|
|
2,946
|
|
|
3,002
|
|
|
4,084
|
|
||
Changes in operating assets and liabilities
|
|
1,742
|
|
|
(1,383
|
)
|
|
465
|
|
||
Net cash (used in) provided by operating activities
|
|
(583
|
)
|
|
(3,928
|
)
|
|
(2,583
|
)
|
||
Investing activities
|
|
|
|
|
|
|
|||||
Purchases of property and equipment
|
|
1
|
|
|
(149
|
)
|
|
(243
|
)
|
||
Equity method investment
|
|
—
|
|
|
(300
|
)
|
|
—
|
|
||
Advances to and investments in subsidiaries
|
|
(9,333
|
)
|
|
(19,900
|
)
|
|
(22,209
|
)
|
||
Net cash used in investing activities
|
|
(9,332
|
)
|
|
(20,349
|
)
|
|
(22,452
|
)
|
||
Financing activities
|
|
|
|
|
|
|
|||||
Tax withholding on restricted stock
|
|
(662
|
)
|
|
(643
|
)
|
|
—
|
|
||
Proceeds from exercise of stock options
|
|
3,745
|
|
|
1,335
|
|
|
211
|
|
||
Proceeds from (repayment of) debt financing
|
|
4,988
|
|
|
(14,900
|
)
|
|
(15,000
|
)
|
||
Other financing costs
|
|
(195
|
)
|
|
—
|
|
|
(103
|
)
|
||
Net Proceeds from IPO
|
|
—
|
|
|
—
|
|
|
72,755
|
|
||
Net cash (used in) provided by financing activities
|
|
7,876
|
|
|
(14,208
|
)
|
|
57,863
|
|
||
Effect of foreign exchange rates on cash, net
|
|
—
|
|
|
(517
|
)
|
|
175
|
|
||
Net (decrease) increase in cash, cash equivalents, and restricted cash
|
|
(2,039
|
)
|
|
(39,002
|
)
|
|
33,003
|
|
||
Cash, cash equivalents, and restricted cash at beginning of year
|
|
6,040
|
|
|
45,042
|
|
|
12,039
|
|
||
Cash, cash equivalents, and restricted cash at end of year
|
|
$
|
4,001
|
|
|
$
|
6,040
|
|
|
45,042
|
|
Supplemental disclosures
|
|
|
|
|
|
|
|||||
Interest paid
|
|
(153
|
)
|
|
(155
|
)
|
|
(1,494
|
)
|
||
Noncash investing and financing activities:
|
|
|
|
|
|
|
|||||
Warrants issued in conjunction with debt issuance
|
|
—
|
|
|
—
|
|
|
1,124
|
|
||
Cashless exercise of preferred stock warrants
|
|
—
|
|
|
—
|
|
|
1,270
|
|
||
Cashless exercise of common stock warrants
|
|
600
|
|
|
—
|
|
|
—
|
|
||
Common stock warrant reclassification to equity
|
|
—
|
|
|
—
|
|
|
3,180
|
|
1.
|
Amendments to Existing Agreement
. As of the Effective Date, the Existing Agreement is hereby amended or modified as follows:
|
a.
|
Section 2 of the Existing Agreement is hereby amended in its entirety to read as follows:
|
b.
|
Schedule 1, Section 1 of the Existing Agreement is hereby amended by inserting at the end of such Section the following new Section 1(c):
|
2.
|
Severability
. Any term or provision of this Amendment that is invalid or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such invalidity or unenforceability without rendering invalid or unenforceable the remaining terms and provisions of the Existing Agreement, as modified by this Amendment, or affecting the validity or enforceability of any of the terms or provisions of the Existing Agreement, as modified by this Amendment, in any other jurisdiction. If any provision of the Existing Agreement, as modified by this Amendment, is so broad as to be unenforceable, the provision shall be interpreted to be only so broad as is enforceable.
|
3.
|
Amendment
. The terms and conditions of this Amendment may be amended or waived only in writing executed by duly authorized representatives of the Parties.
|
4.
|
Counterparts
. This Amendment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same agreement.
|
1.
|
EMPLOYMENT.
|
a.
|
Position and Duties of Executive.
Executive shall continue to serve as the President of APIC, and will faithfully and prudently perform such duties and responsibilities that the Chief Executive Officer of Trupanion, Inc. (“
CEO
”) from time to time may determine appropriate. It is the Parties’ intent that Executive will focus primarily on developing new revenue partnerships for the Company.
|
b.
|
Performance.
During Executive’s employment with the Company, Executive shall devote his professional time, energy, knowledge, skill and reasonable best efforts to the business of the Company.
|
2.
|
AT-WILL EMPLOYMENT.
|
3.
|
COMPENSATION.
|
a.
|
Variable Salary
. On or before the 15
th
of each month, the Company or an affiliate shall pay Executive in accordance with the schedule set out on
Exhibit A
. At the
|
b.
|
Bonus
. The Company shall pay to Executive an annual cash bonus in or about February 2017, subject to the approval of the Board of Directors of Trupanion, Inc., or the compensation committee thereof, as applicable, based on the achievement of (a) corporate performance goals and (b) individual performance objectives as follows: 50% of the bonus is based on the Company’s achievement of objectives and 50% is based on Executive’s individual achievement of quarterly objectives with respect to 2016, as previously defined by CEO. The target amount of this bonus at 100% achievement for both categories will be $96,000. The above-described bonus will be paid only if Executive is an active employee at the time the annual bonus is paid in 2017. Unless agreed otherwise in writing, other than the bonus to be paid in February 2017, the Company will not pay Executive any future annual bonus.
|
c.
|
Stock Options.
All stock options previously granted to Executive will continue to vest according to the terms of the Company’s stock option plan and the terms of the prior grants to Executive. Unless otherwise agreed in writing, going forward the Company will not grant Executive any additional stock options.
|
d.
|
Vacations.
From the Effective Date forward, Executive shall be entitled to accrue up to four weeks of vacation annually. Such vacations shall be taken at times consistent with the effective discharge of Executive’s duties and the reasonable business needs of the Company. Unless specifically stated to the contrary in writing by the Company, unused vacations in any year shall be treated consistently with the policies, rules and regulations adopted by the Company applicable to senior executives of the Company.
|
e.
|
Other Benefits.
During Executive’s employment with the Company, Executive is entitled to participate in any group health insurance plan, 401(k) plan, group life plan, and any other benefit program or policy that is made available, from time to time, to executives of the Company, subject to the terms of the plan documents, as such plans may be modified, amended, terminated, or replaced from time to time.
|
f.
|
Reimbursement of Expenses.
Executive will be reimbursed for all reasonable, out-of-pocket business expenses incurred in the performance of Executive’s duties on behalf of the Company. To obtain reimbursement, expenses must be submitted as soon as practicable with appropriate supporting documentation and will be reimbursed in accordance with the Company’s policies.
|
4.
|
CONFIDENTIAL INFORMATION.
|
a.
|
Continuing on an ongoing basis during Executive’s employment, the Company shall continue to give Executive Confidential Information. Such Confidential Information excludes information that is either in the public domain or was known to Executive prior to the commencement of any employment by the
|
i.
|
Information concerning trade secrets, customers, clients, marketing, business and operational methods of the Company and its customers or clients, contracts, financial or other data, technical data, emails and other correspondence or any other confidential or proprietary information possessed, owned or used by the Company;
|
ii.
|
Sales and marketing information, plans and strategies;
|
iii.
|
Product information, plans and strategies, including pricing methods and information;
|
iv.
|
Employee lists and salary information, personnel evaluations and evaluation procedures;
|
v.
|
Finance strategies, systems, research, plans, reports, recommendations and conclusions;
|
vi.
|
Acquisition or other transactional strategies;
|
vii.
|
Names, arrangements with, or other information relating to the Company’s customers, clients, suppliers, financiers, owners or operators, representatives and other persons who have business relationships with the Company or who are prospects for business relationships with the Company;
|
ix.
|
Cost, operating and other management information systems, and other software and programming.
|
b.
|
In exchange for the Company’s promises to provide Executive with Confidential Information, Executive shall not during his employment with the Company under this Agreement, or at any time thereafter, disclose to anyone else, or publish, or use for any purpose, any Confidential Information, except as: (i) required in the ordinary course of the Company’s business or Executive’s work for the Company, (ii) required by law or court order, or (iii) directed and authorized in writing by the Company.
|
c.
|
Return of Company Property.
At the conclusion of Executive’s employment with the Company, for any reason, Executive shall immediately return and deliver to the Company any and all computers, hard drives, papers, books, records, documents, memoranda, manuals, emails, electronic or magnetic recordings or data, including all copies thereof, laptops, pagers, personal digital assistants, cell phones, corporate credit cards, keys, and/or access cards, and any other property belonging to the Company or any affiliate that are in Executive’s possession, whether prepared by Executive or others. If at any time after termination of Executive’s employment, for any reason, Executive determines that Executive
|
d.
|
The Company is the exclusive owner of all Confidential Information.
|
5.
|
OWNERSHIP AND USE
|
a.
|
The Company shall be the exclusive owner of all Inventions, Materials and Proprietary Rights. For the purposes of this Agreement, “
Invention
” means any product, device, technique, know-how, computer program, algorithm, method, process, procedure, improvement, discovery or invention, whether or not patentable or copyrightable and whether or not reduced to practice, that (a) is within the scope of the Company's business, research or investigations or results from or is suggested by any work performed by Executive for the Company and (b) is created, conceived, reduced to practice, developed, discovered, invented or made by Executive while employed by the Company, whether solely or jointly with others, and whether or not while engaged in performing work for the Company. For the purposes of this Agreement, “
Proprietary Right
” means any patent, copyright, trade secret, trademark, trade name, service mark, maskwork or other protected intellectual property right in any Confidential Information, Invention or Material. For the purposed of this Agreement, “
Material
” means any product, prototype, model, document, diskette, tape, picture, design, recording, writing or other tangible item that contains or manifests, whether in printed, handwritten, coded, magnetic or other form, any Confidential Information, Invention or Proprietary Right.
|
b.
|
Executive assigns and transfers, and agrees to assign and transfer, to the Company all rights and ownership that Executive has or will have in Confidential Information, Inventions, Materials and Proprietary Rights, subject to the limitations set forth in Section 5.f. and in the notice below. Further, Executive waives any Moral Rights that Executive may have in any Confidential Information, Inventions, Materials and Proprietary Rights. For the purposes of this Agreement, “
Moral Rights
” means all rights of paternity, integrity, disclosure and withdrawal, and any other right that may be known as “moral rights”). Executive will take such action (including signature and assistance in preparation of documents or the giving of testimony) as may be requested by the Company to evidence, transfer, vest or confirm the Company's rights and ownership in Confidential Information, Inventions, Materials and Proprietary Rights. Executive agrees to keep and maintain adequate and current written records of all Inventions and Proprietary Rights during the Term. The records will be in the form of notes, sketches, drawings, and any other format that may be specified by the Company. The records will be available to and remain the sole property of the Company at all times. Executive will not contest the validity of any Proprietary Right, or aid or encourage any third party to contest the validity of any Proprietary Right of the Company.
|
c.
|
If the Company is unable for any reason to secure Executive’s signature to fulfill the intent of the foregoing paragraph or to apply for or to pursue any application
|
d.
|
Except as required for performance of Executive’s work for the Company or as authorized in writing by the Company, Executive will not (a) use, disclose, publish or distribute any Confidential Information, Inventions, Materials or Proprietary Rights or (b) remove any Materials from the Company's premises.
|
e.
|
Executive will promptly disclose to the Company all Confidential Information, Inventions, Materials or Proprietary Rights, as well as any business opportunity that comes to Executive’s attention while employed by the Company and that relates to the business of the Company or that arises as a result of Executive’s employment with the Company. Executive will not take advantage of or divert any such opportunity for the benefit of Executive or anyone else either during or after his employment by the Company without the prior written consent of the Company.
|
f.
|
Exhibit C
is a list describing all inventions, original works of authorship, developments, improvements, and trade secrets that were made by Executive prior to Executive’s employment (collectively referred to as “
Prior Inventions
”), which belong to Executive, which relate to the Company's current or proposed business, products or research and development, and which are not assigned to the Company; or, if no such list is attached, Executive represents that there are no such Prior Inventions. If, while employed, Executive incorporates into a Company product, process or machine a Prior Invention owned by Executive or in which Executive has an interest, the Company is granted and shall have a nonexclusive, royalty-free, irrevocable, perpetual, worldwide license to make, have made, modify, use and sell such Prior Invention as part of or in connection with such product, process or machine.
|
6.
|
RESTRICTIVE COVENANTS.
|
a.
|
The covenants contained in this Section 6 are made by Executive in consideration for (i) the Company’s promise to provide Confidential Information to Executive, (ii) the substantial economic investment made by the Company in the Confidential Information and goodwill of the Company, and (iii) the compensation and other benefits afforded by the Company to Executive. To protect the Company’s Confidential Information, Executive agrees to enter into the following restrictive covenants.
|
i.
|
Non-Competition.
Executive agrees that, during Executive’s employment with the Company and during the Restricted Period (defined below), other than in connection with Executive’s duties under this Agreement, Executive will not, without the prior written consent of the Company, directly or indirectly: (1) have any ownership interest in an entity that engages in the business of providing medical and/or health insurance for pets, including, without limitation, acting as a general agent and/or an underwriter of any form of such insurance (“
Pet Health Insurance
”), or (2) engage in executive or managerial duties for an entity that is engaged in the business of Pet Health Insurance, or (iii) otherwise engage accept work, enter into contracts, or provide any services, directly or indirectly, to an entity or individual that is, directly or indirectly, engaged in business of Pet Health Insurance. Notwithstanding the foregoing, during Executive’s employment with the Company and during the Restricted Period, Executive shall be permitted to own, directly or indirectly, solely as an investment, securities of any entity that are publicly traded on any national securities exchange if Executive is not the controlling shareholder, or a member of a group that controls such entity, and directly or indirectly, does not own five percent or more of any class of securities of such entity.
|
ii.
|
Non-Solicitation.
Executive agrees that, during Executive’s employment with the Company and during the Restricted Period, other than in connection with performing duties under this Agreement, Executive will not, directly or indirectly, either as a principal, agent, employee, consultant, officer, director, stockholder, partner, investor, lender or in any other capacity, and whether personally or through other persons:
|
A.
|
Solicit, induce or attempt to solicit or induce, on behalf of himself or any other person or entity, any employee or independent contractor of the Company who had such relationship with the Company at the time of solicitation to
|
B.
|
Solicit, induce or attempt to solicit or induce any client, business partner, or prospective client or business partner, of the Company to curtail their business relationship with the Company.
|
iii.
|
Tolling.
If Executive violates any of the restrictions contained in this Section 6, the Restricted Period will be suspended and will not run in favor of Executive from the time of the commencement of any violation until the time when Executive cures the violation to the satisfaction of the Company, or a court issues a valid temporary restraining order or injunction requiring Executive to comply with his obligations under this Section.
|
iv.
|
Remedies.
Executive acknowledges that the restrictions contained in Section 4 and this Section 6 of this Agreement, in view of the Company’s business and Executive’s position with the Company, are reasonable and necessary to protect the Company’s legitimate business interests, and that any violations of Section 4 and this Section 6 of this Agreement would result in irreparable injury to the Company. In the event of a breach, the Company shall be entitled to (1) a temporary restraining order and injunctive relief restraining Executive from the commission of any breach, (2) recover attorneys’ fees, expenses and costs that the Company incurs in such action, and/or (3) recover any and all damages to which the Company may be entitled at law or in equity as a result of a breach of this Agreement.
|
v.
|
Reformation.
The courts shall be entitled to modify the duration and scope of any restriction contained herein to the extent such restriction would otherwise by unenforceable, and such restriction as modified shall be enforceable. Executive acknowledges that the restrictions imposed by this Agreement are legitimate, reasonable and necessary to protect the Company’s investment in its business and the goodwill thereof. Executive acknowledges that the scope and duration of the restrictions contained herein are necessary and reasonable in light of the time that Executive has been engaged in the business of the Company, Executive’s reputation in the market for the Company’s business, and Executive’s relationships with the customers and business partners of the Company.
|
7.
|
TERMINATION.
|
a.
|
Death.
Executive’s employment hereunder shall terminate upon Executive’s death.
|
b.
|
Disability.
The Company may terminate Executive’s employment hereunder (in accordance with the termination procedures set forth in Section 7.f. upon a determination of Disability of Executive. For purposes of this Agreement, “Disability” means a physical or mental condition that, in the judgment of a duly licensed physician specializing in the area of medicine applicable to any such Disability, and selected in good faith by the Company, prevents Executive from performing the material functions of his position with the Company, even with reasonable accommodation, for a period of not less than 180 consecutive days in any twelve-month period or 270 non-consecutive days in any twelve-month period.
|
c.
|
For Any Reason by the Company.
The Company may terminate Executive’s employment at any time, subject to the termination procedures set forth in Section 7.f.
|
d.
|
For any Reason by Executive.
Executive may terminate Executive’s employment at any time, subject to the termination procedures set forth in Section 7.f.
|
e.
|
For Cause by the Company.
The Company may terminate Executive’s employment hereunder immediately for Cause. For purposes of this Agreement, “
Cause
” is defined as:
|
i.
|
acts or omissions constituting gross negligence, recklessness or willful misconduct on the part of Executive with respect to Executive’s obligations or otherwise relating to the business of the Company;
|
ii.
|
Executive’s material breach of this Agreement;
|
iii.
|
Executive’s conviction or entry of a plea of nolo contendere for fraud, misappropriation or embezzlement, or any felony or crime of moral turpitude or that otherwise negatively impacts Executive’s ability to effectively perform Executive’s duties hereunder;
|
f.
|
Termination Procedure.
Any termination of Executive’s employment by the Company or by Executive (other than termination pursuant to Section 7.a, 7.b. or 7.e) shall be communicated by written Notice of Termination to the other Party hereto in accordance with Section 12 not less than thirty days prior to the termination date, except as otherwise set forth herein. For purposes of this Agreement, a “
Notice of Termination
” shall mean a notice indicating the specific termination provision in this Agreement relied upon as the basis for such termination and setting forth the specific reason(s) for such termination.
|
g.
|
Obligations upon Termination.
|
i.
|
The Company’s Obligations to Executive Upon Termination for Cause.
In the event the Company terminates Executive’s employment for Cause, Executive shall be entitled to receive (i) reimbursement for any unreimbursed expenses properly incurred prior to the Date of Termination and (ii) any earned but unused vacation time through the Date of Termination. Executive will not be entitled to receive the Termination Payments described in Section 7.g.ii.
|
ii.
|
The Company’s Obligations Following Termination Due to Death or Disability, Termination Without Cause by the Company, or Termination by Executive.
In the event the Company terminates Executive’s employment for death or Disability, or without Cause, the Company shall be obligated to pay (i) reimbursement for any unreimbursed expenses properly incurred prior to the Date of Termination, (ii) any earned but unused vacation time through the Date of Termination, and (iii) any Termination Payments. For the purposes of this Agreement, “
Termination Payments
” are defined as the payments to Executive or in the event of Executive’s death to the Graff Marital Trust (or such other persons or entity designated by Executive to receive payments in the event of Executive’s death) over the time period (the “
Termination Payment Period
”) and in the amount set forth on
Exhibit B
. Any payments made under this provision shall be made on the same schedule as if Executive’s employment had not been terminated, although the Company reserves the right in its sole discretion to make any partial month payments together with the final full month payment.
|
iii.
|
Executive’s Obligations to the Company Following Termination.
Except for termination due to death, Disability, or for Misconduct Cause, during the Termination Payment Period Executive agrees, in consideration for the Termination Payments and other valuable consideration, the adequacy and receipt of which Executive acknowledges by executing this Agreement, to reasonably assist the Company to facilitate an orderly transition away from the services Executive previously provided, for a period of up to six months beginning with the Termination Effective Date. It is the intent of the Parties that Executive would spend no more than 25% over an average
|
8.
|
APPLICATION OF SECTION 409A.
|
a.
|
Notwithstanding anything set forth in this Agreement to the contrary, no amount payable pursuant to this Agreement that constitutes a “deferral of compensation” within the meaning of the Treasury Regulations issued pursuant to Section 409A of the Code (the “Section 409A Regulations”) shall be paid unless and until Executive has incurred a “separation from service” within the meaning of the Section 409A Regulations. Furthermore, to the extent Executive is a “specified employee” within the meaning of the Section 409A Regulations as of the date of Executive’s Separation from service, no amount that constitutes a deferral of compensation that is payable on account of Executive’s separation from service shall be paid to Executive before the date (the “Delayed Payment Date”) which is the first day of the seventh month after the date of Executive’s separation from service or, if earlier, the date of Executive’s death following such separation from service. All such amounts that would, but for this Section, become payable prior to the Delayed Payment Date will be accumulated and paid on the Delayed Payment Date.
|
b.
|
The Company intends that income provided to Executive pursuant to this Agreement will not be subject to taxation under Section 409A of the Code. The provisions of this Agreement shall be interpreted and construed in favor of satisfying any applicable requirements of Section 409A of the Code.
However, the Company does not guarantee any particular tax effect for income provided to Executive pursuant to this Agreement.
In any event, except for the Company’s responsibility to withhold applicable income and employment taxes from compensation paid or provided to Executive, the Company shall not be responsible for the payment of any applicable taxes on compensation paid or provided to Executive pursuant to this Agreement.
|
c.
|
Notwithstanding anything to the contrary in this Agreement, the reimbursement of expenses or in-kind benefits provided pursuant to this Agreement shall be subject to the following conditions: (1) the expenses eligible for reimbursement or in-kind benefits in one taxable year shall not affect the expenses eligible for reimbursement or in-kind benefits in any other taxable year; (2) the reimbursement of eligible expenses or in-kind benefits shall be made promptly, subject to the Company’s applicable policies, but in no event later than the end of the year after which such expense was incurred; and (3) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit.
|
9.
|
MODIFICATION.
|
10.
|
SEVERABILITY.
|
11.
|
NO IMPLIED WAIVER.
|
12.
|
NOTICE.
|
13.
|
GOVERNING LAW AND ARBITRATION.
|
14.
|
SUCCESSORS AND ASSIGNMENT.
|
15.
|
NO MITIGATION.
|
16.
|
COUNTERPARTS/ELECTRONIC SIGNATURES.
|
17.
|
SEVERABILITY.
|
18.
|
INTERPRETATION.
|
19.
|
ENTIRE AGREEMENT.
|
|
Monthly Gross Earned Premium in Other Revenue
|
PAYMENT to Executive
|
|
Band ID
|
Gross Earned Premium (GEP)
|
Commission %
|
|
1
|
If the monthly GEP is < $166,666 = No Payment
|
0.000000
|
%
|
2
|
If the monthly GEP is $166,667 or > but < $249,999
|
0.2507330
|
%
|
3
|
If the monthly GEP is $250,00 or > but < $333,332
|
0.3973031
|
%
|
4
|
If the monthly GEP is $333,333 or > but < $416,666
|
0.5012154
|
%
|
5
|
If the monthly GEP is $416,667 or > but < $833,332
|
0.5817478
|
%
|
6
|
If the monthly GEP is $833,333 or > but < $1,233,332
|
0.8312552
|
%
|
7
|
If the monthly GEP is $1,233,333 or > but < $4,166,666
|
0.9375000
|
%
|
8
|
If the monthly GEP is $4,166,667 or > but < $8,333,332
|
1.2500000
|
%
|
9
|
If the monthly GEP is $8,333,333 or > but < $24,999,999
|
1.4062500
|
%
|
10
|
If the monthly GEP is $25,000,000 or >
|
1.5625000
|
%
|
Verbal Description of the process:
|
|
|
|
|
1. Every month Finance captures and records the GEP for all business classified as Other Revenue. For purposes of this Agreement, the Parties agree that when defining “Other Revenue” they will attempt to classify Other Revenue consistent with how the Company records “Other Revenue” business on its financial statements. For the purposes of this Agreement, “
Other Revenue
” is defined as any business (1) where the Company is not directly performing the marketing of the policy to consumers or (2) where the cancellation pattern of a sub-segment of the Company’s business may be positively or negatively affected by the execution or termination of a contract with a person or entity that could result in numerous pets owned by different policyholders enrolling or cancelling over a period of time.
In addition, to avoid confusion regarding potential exceptions or differing interpretations regarding this definition, the Parties agree that APIC’s President and Trupanion, Inc.’s CFO will jointly agree at the inception of each new transaction that might lead to the generation of “Other Revenue” on whether premium arising from that transaction should be eligible for compensation under this Agreement. Once that determination has been made and a transaction has been classified as “included in Other Revenue” for the purposes of this Agreement, all future earned premium associated with that transaction will be included in the monthly earned premium calculation. To avoid any doubt, the Parties agree to record and track earned premium at the transaction level and share this data monthly as accompanying support to the monthly payments being made under this Agreement.
|
||||
2. Once the GEP for the month is known and booked, Finance compares the GEP in the month to the monthly GEP bands described in the above table.
|
||||
3. Once the correct commission band is determined, Finance multiplies the actual GEP in the month by the commission percentage and processes the payment accordingly.
|
||||
Example (1)
|
|
|
|
|
GEP in July 2017 is $1,553,444. That slots into band 7, i.e. above $1,233,333 but less than $4,166,666.
|
|
|||
Pay Executive $1,553,444 * 0.9375% =
|
$14,563.54
|
|
|
|
|
|
|
|
|
Example (2)
|
|
|
|
|
GEP in Sept 2019 is $4,177,000. That slots into band 8, i.e. above $4,166,667 but less than $8,333,332.
|
|
|||
Pay Executive $4,177,000 * 1.25% =
|
$52,212.50
|
|
|
|
|
|
|
|
|
Example (3)
|
|
|
|
|
GEP in Oct 2019 drops to $4,150,000. That slots into band 7 i.e. above $1,233,333 but less than $4,166,666.
|
|
|
||
Pay Executive $4,150,000 * 0.9375% =
|
$38,906.25
|
|
|
|
|
|
|
|
Effective Date of Termination
|
Amount of Payment per Month
|
Number of Months Payable Beginning on the Termination Effective Date
|
Before 1/1/2018
|
None
|
Not applicable
|
After 1/1/2018
|
The average of the monthly amount payable to Executive pursuant to
Exhibit A
over the three full months prior to the Termination Effective Date.
|
Six months plus 0.5 months for each full month of employment completed after 1/1/2018 up to a maximum of 24 months.
|
Title
|
Date
|
Identifying Number
or Brief Description |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TABLE OF CONTENTS
|
Page
|
1
|
DEFINITIONS AND CONSTRUCTION
|
1
|
1.1.
|
Definitions
|
1
|
1.2.
|
Accounting Terms
|
20
|
1.3.
|
Terms Generally
|
20
|
2
|
LOAN AND TERMS OF PAYMENT
|
21
|
2.1.
|
Credit Extensions
|
21
|
2.2.
|
LC and Ancillary Services Sublimit
|
22
|
2.3.
|
Letters of Credit
|
23
|
2.4.
|
Overadvances; Protective Overadvances
|
28
|
2.5.
|
Interest Rates, Payments, and Calculations
|
29
|
2.6.
|
Crediting Payments
|
29
|
2.7.
|
Fees
|
30
|
2.8.
|
Term
|
30
|
2.9.
|
Pro Rata Treatment and Payments
|
30
|
2.10.
|
Illegality; Requirements of Law
|
33
|
2.11.
|
Taxes
|
35
|
2.12.
|
Change of Lending Office
|
39
|
2.13.
|
Substitution of Lenders
|
39
|
2.14.
|
Defaulting Lenders
|
40
|
2.15.
|
Notes
|
42
|
3
|
CONDITIONS OF LOANS
|
42
|
3.1.
|
Conditions Precedent to Closing
|
42
|
3.2.
|
Conditions Precedent to all Credit Extensions
|
43
|
4
|
CREATION OF SECURITY INTEREST
|
43
|
4.1.
|
Grant of Security Interest
|
43
|
4.2.
|
Perfection of Security Interest
|
44
|
4.3.
|
Pledge of Collateral
|
44
|
5
|
REPRESENTATIONS AND WARRANTIES
|
45
|
5.1.
|
Due Organization and Qualification
|
45
|
5.2.
|
Due Authorization; No Conflict
|
45
|
5.3.
|
Collateral
|
45
|
5.4.
|
Intellectual Property Collateral
|
45
|
5.5.
|
Name; Location of Chief Executive Office
|
46
|
5.6.
|
Litigation
|
46
|
5.7.
|
No Material Adverse Change in Financial Statements
|
46
|
5.8.
|
Solvency, Payment of Debts
|
46
|
5.9.
|
Compliance with Laws and Regulations
|
46
|
5.10.
|
Subsidiaries
|
46
|
5.11.
|
Government Consents
|
47
|
5.12.
|
Inbound Licenses
|
47
|
5.13.
|
Shares
|
47
|
5.14.
|
Full Disclosure
|
47
|
5.15.
|
Labor Matters
|
47
|
5.16.
|
Capitalization
|
47
|
5.17.
|
OFAC; Sanctions, Etc
|
47
|
5.18.
|
EEA Financial Institution
|
48
|
6
|
AFFIRMATIVE COVENANTS
|
48
|
6.1.
|
Good Standing and Government Compliance
|
48
|
6.2.
|
Financial Statements, Reports, Certificates
|
48
|
6.3.
|
Inventory and Equipment; Returns
|
50
|
6.4.
|
Taxes
|
50
|
6.5.
|
Insurance
|
50
|
6.6.
|
Accounts
|
51
|
6.7.
|
Financial Covenants
|
51
|
6.8.
|
Registration of Intellectual Property Rights
|
53
|
6.9.
|
Consent of Inbound Licensors
|
54
|
6.10.
|
Creation/Acquisition of Subsidiaries
|
54
|
6.11.
|
Notices
|
54
|
6.12.
|
Capital, Licensing and Compliance Requirements; Financial Covenants
|
55
|
6.13.
|
WICL Segregated Account
|
55
|
6.14.
|
Further Assurances
|
55
|
7
|
NEGATIVE COVENANTS
|
55
|
7.1.
|
Dispositions
|
56
|
7.2.
|
Change in Name, Location, Executive Office, or Executive Management; Change in Business; Change in Fiscal Year; Change in Control
|
56
|
7.3.
|
Mergers or Acquisitions
|
56
|
7.4.
|
Indebtedness
|
56
|
7.5.
|
Encumbrances
|
57
|
7.6.
|
Distributions
|
57
|
7.7.
|
Investments
|
57
|
7.8.
|
Capitalized Expenditures
|
57
|
7.9.
|
Transactions with Affiliates
|
57
|
7.10.
|
Subordinated Debt
|
57
|
7.11.
|
Inventory and Equipment
|
57
|
7.12.
|
No Investment Company; Margin Regulation
|
58
|
7.13.
|
APIC Capital Withdrawals
|
58
|
7.14.
|
Canadian Subsidiaries
|
58
|
8
|
EVENTS OF DEFAULT
|
58
|
8.1.
|
Payment Default
|
58
|
8.2.
|
Covenant Default
|
58
|
8.3.
|
Material Adverse Change
|
59
|
8.4.
|
Attachment
|
59
|
8.5.
|
Insolvency
|
59
|
8.6.
|
Other Agreements
|
59
|
8.7.
|
Judgments
|
59
|
8.8.
|
Misrepresentations
|
60
|
8.9.
|
ERISA Event
|
60
|
9
|
RIGHTS AND REMEDIES OF ADMINISTRATIVE AGENT AND THE LENDERS
|
60
|
9.1.
|
Rights and Remedies
|
60
|
9.2.
|
Power of Attorney
|
62
|
9.3.
|
Accounts Collection
|
62
|
9.4.
|
Administrative Agent Expenses
|
62
|
9.5.
|
Liability for Collateral
|
63
|
9.6.
|
No Obligation to Pursue Others
|
63
|
9.7.
|
Remedies Cumulative
|
63
|
9.8.
|
Demand; Protest
|
63
|
10
|
The Administrative Agent
|
63
|
10.1.
|
Appointment and Authority
|
63
|
10.2.
|
Delegation of Duties
|
64
|
10.3.
|
Exculpatory Provisions
|
64
|
10.4.
|
Reliance by Administrative Agent
|
65
|
10.5.
|
Notice of Default
|
66
|
10.6.
|
Non-Reliance on Administrative Agent and Other Lenders
|
66
|
10.7.
|
Indemnification
|
67
|
10.8.
|
Agent in Its Individual Capacity
|
67
|
10.9.
|
Successor Administrative Agent
|
67
|
10.10.
|
Collateral and Guaranty Matters
|
68
|
10.11.
|
Administrative Agent May File Proofs of Claim
|
69
|
10.12.
|
No Other Duties, Etc
|
69
|
10.13.
|
Survival
|
70
|
11
|
NOTICES
|
70
|
12
|
CHOICE OF LAW AND VENUE; JURY TRIAL WAIVER
|
70
|
13
|
GENERAL PROVISIONS
|
71
|
13.1.
|
Successors and Assigns; Participations and Assignments
|
71
|
13.2.
|
Indemnification
|
76
|
13.3.
|
Time of Essence
|
76
|
13.4.
|
Severability of Provisions
|
76
|
13.5.
|
Amendments and Waivers
|
76
|
13.6.
|
Amendments in Writing, Integration
|
78
|
13.7.
|
Counterparts
|
78
|
13.8.
|
Survival
|
78
|
13.9.
|
Confidentiality
|
79
|
13.10.
|
Costs and Expenses
|
79
|
13.11.
|
Reimbursement by Lenders
|
79
|
13.12.
|
Waiver of Consequential Damages, Etc
|
80
|
13.13.
|
Adjustments; Set-off
|
80
|
13.14.
|
Acknowledgements
|
81
|
13.15.
|
Payments Set Aside
|
81
|
13.16.
|
Releases of Guarantees and Liens
|
82
|
13.17.
|
Patriot Act
|
82
|
13.18.
|
Acknowledgment and Consent to Bail-In of EEA Financial Institutions
|
82
|
14
|
CO-BORROWER PROVISIONS
|
83
|
14.1.
|
Primary Obligation
|
83
|
14.2.
|
Enforcement of Rights
|
83
|
14.3.
|
Borrowers as Agents
|
83
|
14.4.
|
Subrogation and Similar Rights
|
83
|
14.5.
|
Waivers of Notice
|
84
|
14.6.
|
Subrogation Defenses
|
84
|
14.7.
|
Right to Settle, Release
|
84
|
14.8.
|
Subordination
|
85
|
Quarter Ending
|
Minimum Trailing 3 Month Revenue
|
December 31, 2016
|
$40,900,000
|
March 31, 2017
|
$46,970,000
|
June 30, 2017
|
$50,380,000
|
September 30, 2017
|
$53,240,000
|
December 31, 2017
|
$57,420,000
|
Month Ending
|
EBITDA
|
August 31, 2016
|
($1,000,000)
|
September 30, 2016
|
($500,000)
|
October 31, 2016
|
($500,000)
|
November 30, 2016
|
($100,000)
|
December 31, 2016
|
($100,000)
|
January 31, 2017
|
($300,000)
|
February 28, 2017
|
($100,000)
|
March 31, 2017
|
($100,000)
|
April 30, 2017
|
($100,000)
|
May 31, 2017
|
($300,000)
|
June 30, 2017
|
$1.00
|
July 31, 2017
|
$1.00
|
If to Borrower:
|
c/o Trupanion, Inc.
6100 4 th Avenue S, Suite 200 Seattle, Washington 98108 Attn: Chief Financial Officer |
with a copy to:
|
c/o Trupanion, Inc.
6100 4 th Avenue S, Suite 200 Seattle, Washington 98108 Attn: Legal |
If to Administrative Agent:
|
Pacific Western Bank
406 Blackwell Street, Suite 240 Durham, North Carolina 27701 Attn: Loan Operations Manager FAX: (919) 314-3080 |
with a copy to:
|
Pacific Western Bank
406 Blackwell Street, Suite 240 Durham, North Carolina 27701 Attn: General Counsel FAX: (919) 314-3080 |
DEBTOR:
|
TRUPANION, INC. AND TRUPANION MANAGERS USA, INC.
|
SECURED PARTY:
|
PACIFIC WESTERN BANK, as administrative agent, for itself and for the ratable benefit of the Lenders
|
Lender
|
Revolving Commitment
|
Revolving Percentage
|
|
|
|
Pacific Western Bank
|
$20,000,000
|
66.66%
|
Western Alliance Bank
|
$10,000,000
|
33.33%
|
Total
|
$30,000,000
|
100.000000000%
|
Title
|
Country
|
Appl’n Serial No. Filing Date
|
Patent No.
Issue Date
|
Status
|
Pet Insurance System and Method 991110
|
US
|
61/801,404
3/15/2013 |
N/A
|
Converted to US utility and PCT below.
|
Pet Insurance System and Method 995110
|
PCT
|
US14/27042 3/14/2014
|
N/A
|
Filed into national countries
|
Pet Insurance User Interface (Paw Prints user interface design) 995100
|
EPC (Europe)
|
2308841
9/13/2013
|
002308841-00001 09/13/2013
|
Issued.
|
Pet Insurance User Interface (Paw Prints user interface design)
991100 |
US
|
29/449,619
3/15/2013 |
N/A
|
Pending.
|
Pet Insurance System and Method 991111
|
US
|
14/210,079
3/13/2014 |
N/A
|
Pending.
|
Pet Insurance System and Method 991112
|
US CIP
Track One |
14/924,606
10/27/2015 |
N/A
|
Pending.
|
Pet Insurance System and Method 995111
|
Canada
|
2,907,162
3/14/2014 |
N/A
|
Pending.
|
Pet Insurance System and Method 995112
|
Brazil
|
BR1120150237703 3/14/2014
|
N/A
|
Pending.
|
Pet Insurance System and Method 995113
|
Japan
|
NYA
3/14/2014
|
N/A
|
Pending.
|
Pet Insurance System and Method 995114
|
China
|
201480027810.4
3/14/2014 |
N/A
|
Pending.
|
Pet Insurance System and Method 995115
|
EPO
|
14770490.2
3/14/2014 |
N/A
|
Pending.
|
Pet Insurance System and Method 995116
|
Hong Kong
|
16109621.0
8/12/2016 |
N/A
|
Pending.
|
A.
|
100% of the commission charged by the producing Broker, plus;
|
B.
|
3.75% of gross premium on the subject Business, representing reimbursement for premium taxes, plus;
|
C.
|
$800,000 for the calendar year ended December 31, 2016, representing the Reinsured's
|
A.
|
100% of the commission charged by the producing Broker, plus;
|
B.
|
4.00% of gross premium on the subject Business, representing reimbursement for premium taxes, plus;
|
C.
|
$930,000 for the calendar year ended December 31, 2017, representing the Reinsured’s “
Fronting Fee
”.
|
Subsidiary
|
|
Incorporation
|
American Pet Insurance Company
|
|
United States, New York
|
Trupanion Managers USA, Inc.
|
|
United States, Arizona
|
Trupanion Brokers Ontario, Inc.
|
|
Canada, Ontario
|
Wyndham Insurance Company (SAC), Ltd.
|
|
Bermuda
|
(1)
|
Registration Statement (Form S-8 No. 333-197514) pertaining to the 2014 Equity Incentive Plan, 2014 Employee Stock Purchase Plan, and 2007 Equity Compensation Plan of Trupanion, Inc.,
|
(2)
|
Registration Statement (Form S-8 No. 333-202270) pertaining to the 2014 Equity Incentive Plan and 2014 Employee Stock Purchase Plan of Trupanion, Inc., and
|
(3)
|
Registration Statement (Form S-8 No. 333-209550) pertaining to the 2014 Equity Incentive Plan and 2014 Employee Stock Purchase Plan of Trupanion, Inc.
|
1.
|
I have reviewed this Annual Report on Form 10-K of Trupanion, Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
|
5.
|
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
1.
|
I have reviewed this Annual Report on Form 10-K of Trupanion, Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
|
5.
|
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
1.
|
the Annual Report of Trupanion, Inc. on Form 10-K for the year ended December 31, 2016, as filed with the Securities and Exchange Commission, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
2.
|
the information contained in such Form 10-K fairly presents, in all material respects, the financial condition and results of operations of Trupanion, Inc.
|
1.
|
the Annual Report of Trupanion, Inc. on Form 10-K for the year ended December 31, 2016, as filed with the Securities and Exchange Commission, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
2.
|
the information contained in such Form 10-K fairly presents, in all material respects, the financial condition and results of operations of Trupanion, Inc.
|